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ABSTRACT
Inhibins are heterodimeric ligands within the TGFβ superfamily, comprised of an α-subunit
(INHA) and a β-subunit (either INHBA or INHBB) with emergent roles in cancer. Inhibins
are biomarkers of disease burden and prognosis in a subset of cancers and utilize the
coreceptors betaglycan (TGFBR3) and endoglin (ENG) for physiological or pathological
outcomes. Previously, we found inhibin promotes angiogenesis in ovarian cancer however
no mechanism of regulation for inhibin expression in cancer has been established. Hypoxia,
a driver of tumor growth and metastasis, regulates angiogenic pathways that are targets for
vessel normalization and ovarian cancer management. However, toxicities and resistance
to anti-angiogenics can limit their use making identification of new targets vital. Inhibin is
a particularly interesting target for anti-angiogenic therapy within ovarian cancer, as
expression is abrogated in healthy post-menopausal women when compared to
premenopausal women, but markedly elevated in those with ovarian malignancies. Of note,
postmenopausal women make up the majority of ovarian cancer diagnoses, with an average
age of diagnosis of sixty-two. In these patients, targeting inhibin may not present the
toxicities associated with other anti-angiogenic therapies. Here, we look to establish a
mechanism of regulation of inhibin in cancer, define inhibin as a therapeutic target, and
assess the prognostic value of inhibin and its network of receptors (endoglin and
betaglycan) in a pan-cancer analysis. These studies reveal that inhibin, specifically INHA,
is regulated by hypoxia through the transcription factor HIF-1. Hypoxia regulated inhibin
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promotes tumor growth, endothelial cell invasion and permeability. Targeting inhibin in
vivo through knockdown and anti-inhibin strategies robustly reduces permeability in vivo
and alters the balance of pro and anti-angiogenic mechanisms resulting in vascular
normalization. A pan-cancer, bioinformatics analysis revealed gene alterations and
identified cancer cell lines and types that were most dependent and impacted by members
of the inhibin network. Expression of these markers was predictive of both survival and
response to chemotherapeutics. Using cancer types where inhibin, endoglin and betaglycan
were predictive of survival, gene signature analysis was performed to obtain a highly
accurate prognostic model and to determine correlated pathways.

Ultimately, these

findings provide new insights into the therapeutic potential of inhibin as an anti-angiogenic
target in ovarian cancer and shed light on the importance of the inhibin-endoglinbetaglycan network in other cancer types as well.
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CHAPTER 1
INTRODUCTION AND BACKGROUND
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1.1. Structure and Function of Inhibins
Inhibins are dimeric members of the TGF superfamily originally discovered and
named for its ability to suppress FSH secretion and activin signaling1-3. Inhibins are
heterodimers linked by a disulfide bond made up of an alpha subunit (INHA) and a beta
subunit (INHBA or INHBB) giving rise to either inhibin A (INHA/INHBA) or inhibin B
(INHA/INHBB)2,4,5 (Figure 1.1A). Inhibin has a common beta subunit with fellow TGF
member activin however activins are comprised of homodimers of the beta subunits,
forming activin A (INHBA/INBHA) or activin B (INHBB/INHBB) (Figure 1.1C). Both
alpha and beta subunits of inhibin are synthesized as precursor molecules with large,
cleavable pro-domains5,6 (Figure 1.1A). The precursor inhibin subunit contains a prodomain and N domain that are both cleaved separately to produce the mature 18kDa C
domain. The beta subunit has a large N-terminal pro-domain that is cleaved to produce
the mature 13kDa A or B protein (Figure 1.1A). Interestingly, cleavage of the inhibin
subunit is not required for biological activity of inhibin protein as non-cleavable mutants
retained ability to inhibit FSH secretion6.
Inhibin (inhibin) is primarily expressed and secreted in the gonads, specifically
by the granulosa cells in ovarian follicles and the Sertoli cells in the testes, in females and
males respectively7-10. Expression of inhibin is also found outside of the gonads
including the pituitary10,11, prostate12, and adrenal glands10,13, lung11, liver, kidney, and
bone10 indicating biological roles outside of the reproductive organs. However,
circulating inhibin is primarily produced by the gonads as removal of these organs in
mice results in undetectable levels of serum inhibins14. Females produce both inhibin A
and inhibin B. Production of either inhibin A or B driven by beta subunit expression with
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the dominant follicles and corpus luteum producing inhibin A and the small antral
follicles producing inhibin B15-17. In males, however, inhibin B is the only detectable
form of inhibin18.
The use of transgenic mice provided much insight into the physiological function
of inhibin. INHA-/- mice form gonadal tumors by four weeks that secrete increased levels
of activin resulting in tumor cachexia/wasting syndrome and death19,20. However,
removal of the gonads from these animals still results in lethality as they develop adrenal
cortical tumors20. These mice are also infertile and display high levels of FSH indicating
roles in reproduction and in the regulation of FSH19. Overexpression of INHA (inhibin)
in mice results in a decrease in ovulating oocytes, corpus lutea, and antral follicles in
females, and decreased sperm count in males further reinforcing the role of inhibin in
reproductive function21,22.
Inhibin is unique in the TGF family as it is the only endocrine hormone in
addition to having paracrine effects. One of inhibin’s primary functions in adults occurs
in regulating the hypothalamic-pituitary-gonadal (HPG) axis through a negative feedback
loop. FSH and LH produced by the pituitary gland are released to regulate gonadal
function. In response to FSH, INHA expression is increased and inhibin is secreted from
the Sertoli cells and granulosa cells in the gonads23. In regulating the HPG axis, inhibins
act in an endocrine manner where inhibins secreted from the gonads travels to the
pituitary (specifically the gonadotrophs) to decrease FSH production by antagonizing
activin signaling24-26. This mechanism of action effects spermatogenesis, folliculogenesis,
menstrual cycles and menopause5,27.
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During folliculogenesis, follicles are recruited from a primordial pool to form a
single oocyte which is surrounded by theca cells, granulosa cells, and stromal cells that
regulate the hormonal environment. Inhibin levels cycle throughout this process with
inhibin B levels peaking during the early follicular and luteal phases while inhibin A
peaks during midluteal phase14,28. Inhibin B production during the early follicular phase
serves to down-regulate FSH receptor expression and slow oocyte maturation29. Inhibin
A secretion by the corpus luteum has been shown to support follicular dominance during
the mid-luteal phase30. The rise and fall of inhibin levels during women’s menstrual cycle
is marked by a sharp decline upon the onset of menopause. Depletion of the ovarian
follicles results in reduced inhibin levels and subsequent increase in FSH levels driving
the menopause transition31.

1.2. Transcriptional Regulation of INHA
Inhibin expression is modulated by the gonadotropins FSH and LH. FSH
increases intracellular cAMP levels by activating G-protein coupled receptors32.
Intracellular cAMP accumulation promotes PKA signaling and downstream
phosphorylation of the transcription factor CREB (cAMP responsive binding element
binding protein) that binds to consensus CRE (cAMP responsive element) on target genes
to promote transcriptional activation33. The INHA promoter contains a functional CRE
that regulates transcription of the inhibin subunit34. The transcription factors SF-1
(steroidogenic factor-1) and LRH-1 (liver receptor homolog 1), both members of the
NR5A nuclear receptor family, have been shown to act synergistically with CREB and to
enhance INHA transcription in granulosa cells35,36. These transcription factors utilize the
same binding site and switch which one is occupying this site based on cAMP levels and
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subsequent downstream signaling of MAPK and PI3K pathways 36. In adrenal cortical
cells, SF-1 can act synergistically with -catenin to increase INHA transcription in
response to Wnt signaling37. Interestingly, the Wilms’ Tumor Gene 1 (WT1) can act
synergistically with SF-1 in Sertoli cells to promote INHA transcription but acts to
decrease INHA expression in granulosa cells38,39. Members of the GATA family of
transcription factors have also been shown to cooperate with LRH-1 to promote FSH
induced INHA transcription40 as well as cooperation with SMAD3 in response to TGF41.
Suppression of INHA occurs through the CCAAT/enhancer-binding protein and inducible
cAMP early repressor (ICER) which competitively compete with CREB for binding to
the CRE on the INHA promoter42.

1.3. Inhibin Signaling Pathway and Mechanism of Action
Inhibin’s signaling pathway is still being delineated, as we have made new
discoveries in this field in recent years. The most characterized mechanism of action for
inhibin occurs through functional antagonism of activin signaling (Figure 1.2A). Activin
signals by binding the TGF type II receptor, ACTRII, which phosphorylates and
activates the type I receptor, ALK4/ALK7, resulting in downstream phosphorylation of
intracellular SMAD2/3 proteins43. Inhibin competes for binding with activin to ACTRII
through its beta subunit, which is shared with activin, to prevent activation of this
signaling cascade44-47. Since activin has two beta subunits capable of binding ACTRII, it
has a 10-times higher affinity for the receptor than inhibin48. Inhibin is able to overcome
this through binding of betaglycan, a type III TGF co-receptor, through its alpha subunit
which increases inhibins affinity for the type II receptor thus allowing antagonism of
activin signaling49 (Figure 1.2A). Betaglycan is crucial to inhibins function, as siRNA
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knockdown and immunoneutralization of betalgycan inhibits inhibin’s ability to suppress
FSH secretion and activin signaling in gonadotropes49-51. Mutation of the of the
betaglycan binding site on inhibin significantly reduced both inhibin A and inhibin B
ability to repress FSH secretion and activin signaling further cementing the role for
betaglycan in inhibin’s biological function52,53. In addition to binding betaglycan,
inhibin can also bind ALK4 through its N-terminus to antagonize activin signaling54.
Free inhibin and an inhibin N-terminal peptide were able to functionally inhibit activin
signaling representing a model where inhibin can antagonize activin as a free alpha
subunit54-56.
Recently, we demonstrated paracrine signaling effects of inhibin on endothelial
cells57. Inhibin is able to induce SMAD1/5 signaling in endothelial cells, dependent on
the type III TGF co-receptor endoglin and type I receptor ALK157 (Figure 1.2B).
Endoglin is expressed in proliferating endothelial cells while ALK1 is also highly
expressed in endothelial cells and is used by other superfamily members like BMP9/10
and TGF for SMAD1/5 activation58-61. We were unable to show that inhibin directly
binds to either of these receptors however inhibin did induce stable complex formation
between ALK1 and endoglin57 (Figure 1.2B). More research is needed to further
elucidate the roles these receptors, along with a potential type II receptor, play in inhibin
signaling in endothelial cells.

Chapter 1.4. Inhibin as a diagnostic marker in cancer
Serum total inhibin levels, consisting of free inhibin, inhibin A, and inhibin B,
are used as a biomarker for ovarian cancers. Ovarian cancers are divided into subtypes
depending on the cell type of origin. Epithelial cancers account for between 85-90% of
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ovarian cancers with serous being the most common type followed by endometroid,
mucinous, and clear cell carcinoma62. Germ cell and stromal tumors make up the other
subtypes but are much less common that epithelial cancers. Total inhibin levels were
originally found to be elevated in granulosa cell tumors, the most common type of
stromal ovarian cancer, with inhibin B being later discovered as the main form of inhibin
produced by these tumors63-66. Serum inhibin levels are elevated in mucinous tumors and
represent a good diagnostic marker, but inhibin levels alone are not an effective
diagnostic tool for non-mucinous epithelial tumors66,67. However, when used in
combination with CA-125, another ovarian cancer biomarker, serum inhibin levels
accurately detect 95% of ovarian cancers66,68. Inhibin’s utility as a biomarker is limited to
post-menopausal women. Pre-menopausal women still express and secrete inhibin in a
cyclic manner making it difficult to derive baseline values for comparison66,69.
Consistent with findings of elevated serum inhibin levels in epithelial ovarian cancer
patients and previous studies70-72, we demonstrated increased inhibin expression across
mucinous, endometroid, and serous ovarian cancer tissues compared to non-cancerous
ovarian tissues57. Elevated inhibin levels have also been discovered in other cancer types
including gastric73, pancreatic74, hepatocellular carcinomas75, prostate76,77, and
adrenocortical tumors78,79, indicating potential roles for inhibin outside ovarian cancer
that need to be further explored.

1.5. Roles for inhibins in cancer
While inhibins have been used as a diagnostic for ovarian cancer for decades,
roles for inhibin in the context of tumor progression are still being discovered. Originally
thought to have tumor suppressor functions, as INHA-/- mice developed gonadal tumors,
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more recent evidence demonstrates inhibin promotes tumorigenesis pointing to complex
roles for inhibin in cancer that require further studies 19,57,80. We observed significant
inhibin staining in stromal cells of ovarian cancer tissues and tissues with higher
inhibin expression correlated with micro-vessel density, indicating potential roles for
inhibins in angiogenesis57. Consistent with this, we found that inhibin promotes
angiogenesis in an ALK1/ENG dependent manner. Knockdown of inhibin reduced
tumor burden and ascites fluid formation and conditioned media from inhibin
knockdown cells reduced angiogenesis compared to conditioned media from cells
expressing inhibin57. Recently, our findings about inhibin expression being more
localized in stromal cells of serous, mucinous, and endometrial tumors was confirmed 80.
However, in clear cell carcinomas, inhibin distribution was also found in the tumor
epithelial cells along with stromal cells. The inhibin expressing population of tumor
cells was found to be less proliferative, more resistant to chemotherapy, more stem-like,
and had more angiogenic potential80. Patients that had inhibin expressing tumor cells
had decreased overall survival and disease-free survival indicating inhibin is an
unfavorable prognostic marker80.
In prostate cancer, inhibin was originally thought to be a tumor suppressor as
well. Inhibin expression was seen in non-malignant and benign prostate tissues however
in malignant regions inhibin expression was suppressed81. Similarly, prostate cancer
cell lines did not express inhibin and did not respond to exogenous treatment with
inhibin A82. Malignant prostate cancer tissue showed significant promoter methylation
compared to nonmalignant/benign tissue and de-methylation of the INHA promoter in
prostate cancer cell lines that did not express inhibin was able to restore expression76,83.
8

However, more recent studies suggest a more complex role for inhibin in prostate
cancer as elevated levels were seen in malignant tissues, including expression in the
stromal cells, and inhibin expression was associated with poor prognosis77,84,85.
Risbridger et. al hypothesized that inhibin might be an early tumor suppressor in
prostate cancer but promotes tumorigenesis and metastasis as the disease progresses 84.
This hypothesis was confirmed later as inhibin overexpression in androgen dependent
prostate cancer cells (representing early stage disease) reduced tumor growth while in
androgen independent cells (representing late stage metastatic disease) inhibin
promoted tumor growth, metastasis, and lymph angiogenesis77.
The role of inhibin has also been explored in adrenocortical cancers. Studies in
INHA-/- mice point toward inhibin being a tumor suppressor. INHA-/- mice that have
been castrated develop adrenocortical tumors derived from pluripotent progenitor cells
that differentiate into gonadal-like cells driven by changes in activin signaling and LH
due to the lack of inhibin20,86,87. However, differing inhibin levels and inhibin
expression patterns in adrenal cortical tumors indicate a more complicated role. Inhibin
appears to be elevated in some tissues, decreased in others, or unchanged between normal
and malignant78,88-92. As in prostate cancer, aberrant methylation of the INHA promoter
has been reported and is associated with decreased IHNA expression79. Taken together,
this evidence points to potential roles for inhibins in adrenocortical cancers that need
further exploration.

1.6. Hypoxia and Angiogenesis in Ovarian Cancer
Angiogenesis, the formation of blood vessels from pre-existing ones, is a vital
process during growth and development that provides nutrients and oxygen to tissues.
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Similarly, in cancer pathology, solid tumor growth and metastasis are also dependent on
blood vessels and angiogenesis for vital resources93. Tumor vasculature is often
characterized by inefficient oxygen delivery, leaky vessels, and stiffening of the
extracellular matrix (ECM), leading to build-up of ascites fluid and metastasis by
allowing cells to penetrate the blood vessels94-96. Anti-angiogenic therapy, specifically
Bevacizumab (an anti-VEGF antibody) in combination with platinum-based
chemotherapy, has shown to significantly improve progression free survival and overall
survival in ovarian cancer patients97-102. Clinical data attributes the benefits seen in
combination therapy to a decrease in vascular permeability and normalizing of the tumor
vasculature improving drug delivery to the tumor95,103. However, the efficacy of antiangiogenic therapy is hindered by toxicities like hypertension and arterial
thromboembolism making identification of new targets of the tumor vasculature critical97102.

Hypoxia is a fundamental regulator of angiogenesis in cancer, controlling the
expression of pro-and anti-angiogenic genes that drive tumor growth, metastasis, and
immune evasion104. Intratumor hypoxia drives changes in the blood vessels that lead to
altered permeability, build-up of fluid and ascites in ovarian cancer, and metastasis by
facilitating intra/extravasation of tumor cells104,105. Staining of hypoxic regions within
ovarian cancer patients found 46% of patients were experiencing intratumor hypoxia
below 1% O2106. During ovarian cancer metastasis, tumor cells shed from the ovary to
form spheroids to spread through the peritoneum. Malignant ascites formed as a result of
leaky vasculature, has been shown to be a hypoxic environment and aids in the spread of
the shed spheroids which have also been shown to be hypoxic105,107,108.
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Hypoxia regulates angiogenesis through the HIF proteins, a family of
transcription factors that promote expression of angiogenic genes109. The active HIF
transcription factor is made up of an alpha subunit, most commonly HIF-1 or HIF-2,
and a shared beta subunit, HIF110. Under normal oxygen tensions, the alpha subunit is
marked for degradation by prolyl hydroxylases that require oxygen to function. Under
hypoxic conditions, the prolyl hydroxlyases do not function resulting in stabilization of
the alpha subunit where it can translocate to the nucleus111. The active HIF transcription
factor binds to hypoxia response elements (HRE’s) of downstream target genes to
regulate transcription112. In ovarian cancer patients, increased HIF-1 expression has
been shown to be an unfavorable prognostic indicator including correlations with worse
overall survival and progression free survival113,114. Elevated HIF-1 has also been
shown to be correlated with resistance to cisplatin in ovarian cancer patients and
knockdown of HIF-1 in cisplatin resistant ovarian cancer cell lines restored sensitivity
to cisplatin115,116.
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Figure 1.1. Structure of inhibin. A) Inhibin is a hetero dimer comprised of an alpha
subunit (INHA) and a beta subunit (INHBA or INHBB) which form inhibin A or inhibin B,
respectively. Both alpha and beta subunits are synthesized as precursors, containing
cleavable pro-domains. The alpha subunit also has a cleavable N domain. The mature
form of inhibin A/B are shown below. B) Inhibin can also exist as a free monomer in both
precursor form and mature form. C) Activins are formed as homodimers of either IHNBA
or INHBB, forming activin A or activin B.
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Figure 1.2. Inhibin signaling diagram in epithelial and endothelial cells. A) In
endothelial cells, inhibin can antagonize activin signaling through two different
mechanisms. On the left, inhibin binds the type III co-receptor, betaglycan, through the
alpha subunit which increases inhibin’s affinity to bind the type II receptor, ACTRII,
through the beta subunit. The formation of this complex competes with activin for binding
to ACTRII thus preventing downstream SMAD2/3 activation. On the right, inhibin can
bind ALK4 through the alpha subunit to prevent recruitment of this receptor by activin thus
inhibiting downstream SMAD2/3 activation. B) In endothelial cells, inhibin induces
complex fomation between the type III coreceptor, endoglin, type I receptor, ALK1, to
activate downstream SMAD1/5 signaling.

13

CHAPTER 2
HYPOXIA INDUCED INHIBIN PROMOTES TUMOR GROWTH AND
VASCULAR PERMEABILITY IN OVARIAN CANCERS 1

1

Horst, B. et al. Hypoxia induced inhibin promotes tumor growth and vascular
permeability in ovarian cancers. Accepted article. Commun. Biol.
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2.1 Introduction
Changes in angiogenesis are associated with metastasis in most cancers, including
ovarian cancers, with significant impact on tumor progression and ascites development in
advanced disease117,118. As such, anti-angiogenic therapies have had significant impact in
the management of ovarian cancers119. However, their effectiveness can be frequently
limited due in part to toxicities and acquired resistance, leading to challenges with long
term use and marginal improvements in overall survival119. Discovery of new and safer
angiogenic targets is thus critical.
TGF family members, particularly BMP9 and TGF, are the most examined
regulators of angiogenesis but have not been effective as targets for angiogenic therapy due
to their pleiotropic functions in cancer and normal physiology120,121. Similar to TGF and
BMP9, activins’ have controversial and context dependent roles in angiogenesis.
Specifically, activin A has been shown to increase VEGF induced angiogenesis in some
instances122 and in others has been demonstrated to inhibit angiogenesis123. Inhibins’ are a
distinct and unique member of the TGF family as the only endocrine hormone and a
functional heterodimer of an alpha () subunit (INHA) and a beta () activin subunit
(INHBA or INHBB) forming either inhibin A or inhibin B respectively5. Inhibins’ are
distinct from activins which are comprised of homodimers of either beta subunit5. Inhibin
is synthesized as a pro-peptide with a pro-domain, N region, and C region. The prodomain and N region can be cleaved to produce the mature Inhibin subunit comprising
the C region. Physiological Inhibin production by the sertoli cells of the testes,
granulosa cells of the ovary, and the adrenal and pituitary glands 10 is regulated primarily
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by FSH and LH124,125 via a cAMP-PKA pathway resulting in cAMP response element
binding (CREB) to the cAMP response element (CRE) on the INHA promoter126.
While inhibin levels (inhibin A and B) cycle across the lifespan of healthy females
and dramatically decrease at the onset of menopause127, elevated inhibin levels are found
in ovarian, gastric, hepatocellular, and prostate cancers 73,75,77,128. Total inhibin protein
levels comprising free inhibin, inhibin A and inhibin B are also an established diagnostic
marker alone and/or in combination with CA125, for ovarian cancers 66 and have been
proposed as a potential tumor specific target for therapy5,57,77,128,129,. Inhibin levels are
also predictive of survival in multiple cancer types with gene signatures that correlate with
INHA expression, providing a highly accurate prognostic model for predicting patient
outcomes129. However, the mechanism of inhibin expression in cancers have not been
delineated.
Hypoxia is a key mediator of angiogenic responses, regulating pro-and antiangiogenic genes impacting tumor growth, metastasis, and immune evasion104 and is driven
by the hypoxia inducible factor (HIF) family of transcription factors. Hypoxia induced
changes, specifically in tumors, are characterized by inefficient oxygen delivery, leading
to leaky vessels, and altered permeability, build-up of fluid and ascites in ovarian cancer,
and metastasis by facilitating intra/extravasation of tumor cells104,105. We previously
reported decreased ascites accumulation in mice bearing tumor cells with INHA
knockdown57, indicating a potential role for inhibin in regulating metastasis and vascular
functions, a key contributing factor to ascites accumulation. Moreover, inhibin secreted by
tumor cells induces angiogenesis via SMAD1/5 signaling in endothelial cells in a paracrine
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manner dependent on the type III TGF receptor endoglin/CD105 and the type I TGF
receptor ALK157.
To precisely delineate inhibin’s significance in cancer and mechanism of action,
we now determine the impact of hypoxia, a key mediator of the angiogenic and metastatic
response in cancer104, and the contribution of inhibin to the hypoxia adaptive response. We
discover that hypoxia in ovarian xenograft tumors, cancer cells, and patient samples leads
to an increase in inhibin synthesis in a hypoxia inducible factor (HIF) dependent manner.
We find that hypoxia induced tumor growth and vascular permeability in vivo is driven by
inhibin. Moreover, intervention using an antibody based therapeutic strategy to inhibin can
suppress hypoxia driven tumor biology. Mechanistically, inhibin promotes vascular
permeability via endoglin and ALK1. Notably, we also describe for the first time using
sensitive biophysical methods the nature and stability of the endoglin and ALK1 interaction
at the cell surface in response to inhibin. Our findings not just strongly implicate inhibins
as part of the hypoxia adaptive response, but also suggest anti-inhibins’ as an alternative
or companion to current anti- angiogenic therapies that may not be well tolerated.

2.2 Materials and Methods
Cell Lines and Reagents: Ovarian epithelial carcinoma cell lines were obtained as
described in resource Table 2.1 and were from ATCC, the NCI cell line repository through
an MTA, or were as indicated. Cell line authentication was performed at the Heflin Center
for Genomic Science Core Laboratories at UAB. HMEC-1s were grown per ATCC
instructions. COS7 cells were grown in Dublecco’s modified Eagle’s medium with 10%
FBS, 100 U penicillin/streptomycin and L-glutamine. Mouse embryonic endothelial cells
(MEEC) WT and ENG -/- were grown as previously described130. Epithelial carcinoma cell
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lines HEY, OVCA420, SKOV3 and PA1 were cultured in RPMI-1640 containing Lglutamine, 10% FBS and 100 U of penicillin-streptomycin131. OVCAR-5 and HEK293
were cultured in DMEM containing 10% FBS and 100U of penicillin streptomycin.
ID8ip2Luc was a kind gift from Jill Slack-Davis132 and cultured in DMEM containing 4%
FBS, 100U of penicillin streptomycin, 5g/mL of insulin, 5g/mL of transferrin, and
5ng/mL of sodium selenite. All cell lines were maintained at 37°C in a humidified
incubator at 5% CO2, routinely checked for myco-plasma and experiments were conducted
within 3–6 passages depending on the cell line. For hypoxia experiments, a ProOx Model
C21 was used and set to 0.2% O2 and 5% CO2. Anti-inhibin PO/23 and R1 antibodies were
obtained from Oxford-Brookes university through an MTA and from Biocare Medical.
INHA promoter driven luciferase reporter construct was generated through restriction
cloning into pGL4.10 luciferase plasmid. Primers were designed to 547 base pairs of the
INHA promoter containing the first HRE site with Nhe1 and Xho1 restriction sites on the
ends. Insert was amplified from PA1 genomic DNA. Insert was ligated into pGL4.10
plasmid with T4 DNA ligase and INHA promoter region was verified through Sanger
sequencing. Additional details on resource is provided in Table 2.1.
Generation of cell lines: INHA and ARNT knockdown were generated in HEY cells
infected with shRNA lentivirus, followed by selection in 2.5 μg/ml Puromycin and stable
cell lines maintained in 1 μg/ml Puromycin. Luc/GFP cell lines were generated using
pHIV-Luc-ZsGreen construct. Transient DNA transfections in HEK293 were performed
using Lipofectamine 3000. siRNA transfections were performed using RNAiMax.In
HEK293 transfections, single siRNA was used while pooled siRNA was used in HEY and
OV90 transfections.

Lentiviral particles were generated at the Center for Targeted
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Therapeutics Core Facility at the University of South Carolina. shRNA and siRNA
sequences are listed in Table 2.2.
RNA Isolation and RT-qPCR: Total RNA was harvested using Trizol/Chloroform
extraction. RNA was transcribed using iScript Reverse Transcription Supermix and iTaq
Universal SYBR Green Supermix. Expression data was normalized to RPL13A. qRT-PCR
primer sequences are listed in resource Table 2.3.
ELISA: Inhibin ELISA’s were performed according to the manufacturer’s instructions for
the quantitative measurement specifically of total inhibin protein (does not detect activin),
that detects inhibin A (dimer of INHA/INHBA), inhibin B (dimer of INHA/INHBB), and
free inhibin alpha subunit (INHA), from conditioned media of tumor cells. Cells were
grown to 80% confluency in 24 well plates before media was replaced with fresh full serum
media. Cells were placed in hypoxia chamber for 24hrs and media was collected and
concentrated using Amicon Ultra centrifugal filter.
IN VITRO ASSAYS
In vitro Permeability Assay was adapted from Martins-Greene133. 1x105 HMEC-1 cells
were plated onto a Matrigel coated 3M trans-well filter in full serum media. After 24h
hours, a second layer of 1x105 HMEC-1 was plated on top to obtain a confluent monolayer
of cells. After an additional 24hrs, media was replaced with serum free media in the top of
the trans-well and either conditioned media (with 2g of either R1, PO/23, or IgG) or serum
free media containing growth factor in the bottom chamber as indicated in legends. FITCdextran was added to the lower chamber (10g/ml). At indicated time points 10L aliquots
were taken from the top chamber in triplicate and measured using microplate reader for
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FITC-dextran passage. At end point, filters were stained with crystal violet to confirm equal
monolayers were achieved.
Trans-well Migration Assay: 75 000 HMEC-1 were plated on a fibronectin coated
(10g/mL) 8M trans-well filter in serum free media. Conditioned media (with 2g of
either R1, PO/23, or IgG) or serum free media containing 1nM inhibin A or VEGF A was
used as a chemoattractant in the bottom chamber. After 24hrs, unmigrated cells were
scraped off the apical side, migrated cells were fixed in methanol:acetic acid, and nuclei
were stained with Hoechst. Three random images were taken per filter using 10X objective
on EVOS M7000 microscope. Nuclei were counted using ImageJ.
Trans-endothelial Migration Assay: HMEC-1 were grown on 8m trans-well filters as
per permeability assay. HMEC-1 monolayer was treated with 1nM inhibin A or untreated
for four hours. After four hours of treatment, 150 000 HEY-LucGFP expressing cells were
plated on top of the HMEC-1 monolayer and allowed to invade for 18hrs. Filters were fixed
in 4% paraformaldehyde, cells on the apical side of the filter were scraped off, and filters
were mounted on glass slides for imaging. Migration of GFP+ cells was visualized using
10x objective on EVOS M7000 microscope. Three random fields were captured per filter
and GFP+ cells were counted using ImageJ software. Thresholding, circularity, and size
gating were used to exclude unmigrated cells and artifacts.
Chromatin Immunoprecipitation protocol was adapted from ABCAM. Briefly, OV-90
or OVCAR-5 cells were grown in 150cm2 dishes until 80% confluency was reached. Cells
were kept under normoxia or placed in the hypoxia chamber set at 0.2% O 2 for either 12hrs
(OVCAR-5) or 24hrs (OV-90). DNA was crosslinked using 0.75% formaldehyde and
sheared

by

sonication

to

fragment

sizes
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between

100-400bp.

DNA

was

immunoprecipitated with Dyna-beads and either HIF-1 antibody or Normal Rabbit IgG
as a control. DNA was purified using Purelink PCR Purification kit and amplified using
RT-qPCR with ChIP primers.
Luciferase Assay: HEK293 cells were seeded into 24 well plate and co-transfected with a
luciferase reporter containing 547 base pairs of the INHA promoter (pGL4.10 INHA) and
a SV40 (Renilla internal control vector). For HIF-1 overexpression, cells were also cotransfected with pcDNA3-HA-HIF1aP402A/P564A or PCDNA3.1. One day after
transfection, cells were left in a normoxia incubator or moved to hypoxia chamber (0.2%
O2) for 24hrs. Luciferase activity was measured using the Dual Luciferase Reporter Assay
System by calculating the ratio between luciferase and Renilla and normalized to normoxia
or PCDNA3.1 as indicated in legends.
Immunofluorescence: HMEC-1 cells were grown to confluence on fibronectin (10g/mL)
and treated with either 1nM inhibin A or VEGF A for 30 minutes in serum free media.
Cells were fixed in 4% paraformaldehyde and permeabilized with 0.2% TritonX-100,
followed by blocking with 5% BSA in PBS for 1hr. VE-cadherin was labeled with antiVE-cadherin antibody overnight at 4C followed by AlexaFluor 488 secondary antibody.
F-actin was stained with rhodamine-phalloidin and nuclei were labeled with DAPI.
Immunofluorescence imaging was performed on EVOS M7000 microscope or Nikon A1
confocal microscope. Actin fibers were quantified by measuring anisotropy using the
FibrilTool Plugin in ImageJ134.
VE-cadherin Internalization: HMEC-1 cells grown to confluence on fibronectin
(10g/mL) coated glass coverslips. Cell surface VE-cadherin was labeled with anti-VEcadherin antibody at 4C for 30 minutes, washed with ice-cold PBS, and incubated at 37C
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for 30 minutes with 1nM inhibin A, 1nM VEGF A, or serum free media. After
internalization was stimulated with growth factor at 37C, anti-VE-cadherin antibody on
the cell surface was removed with mild acid wash. Internalized VE-cadherin was visualized
by immunofluorescence microscopy. Internalized VE-cadherin was quantified using
BlobFinder software135,136. Nuclei and cytoplasm were delineated and the number of
signals per cell was used to quantify internalized VE-cadherin fluorescence.
Cell Surface Biotinylation: Briefly, MEEC WT or /ENG-/- were grown to confluence on
gelatin coated dishes. Cell surface proteins were labeled with 2mg/mL Sulfo-NH-SS biotin
for 30 min at 4°C. After labeling, cells were treated with 1nM inhibin A or untreated in
serum free media for 30 min at 37°C or left at 4°C for cell surface control samples. After
treatment, cell surface biotin was removed with 20mM MESNA buffer and internalized
biotin labeled protein was isolated with neutravidin resin. Internalized biotin labeled VEcadherin was detected by Western Blot.
Epitope-tagged plasmids and transfection of COS7 cells for patch/FRAP studies
The following plasmids were donated by Prof. G. C. Blobe, Duke University Medical
Center: HA-tagged endoglin (endoglin-L) in pDisplay, myc-endoglin generated by PCR
incorporation of the myc tag sequence into untagged endoglin in pDisplay and re-cloned
in pcDNA3.1, and HA- or myc-tagged ALK1 in pcDNA3.1137. Human ALK4 with Cterminal myc-DDK tags in pCMV6 was obtained from OriGene Technologies (Rockville,
MD), and subcloned into pcDNA3.1 by PCR followed by restriction digest and re-ligation.
A stop codon was introduced at nucleotide 1516 to delete the C-terminal tags to generate
untagged ALK4. This was followed by insertion of N-terminal HA tag by overlapping PCR
after nucleotide 72 to generate extracellularly tagged HA-ALK4. All constructs were
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verified by sequencing. COS7 cells were transfected using TransIT-LT1 Mir2300
according to manufacturer's instructions. For Patch/FRAP experiments, cells grown on
glass coverslips in 6-wells plates were transfected with different combinations of these
vectors encoding myc- and/or HA-tagged receptor constructs. The amounts of the vectors
(between 0.5 and 1 g DNA) were adjusted to yield similar cell surface expression levels,
determined by quantitative immunofluorescence.
Fluorescent antibody labeling and IgG-mediated cross-linking for patch/FRAP:
COS7 cells were transfected with various combinations of the above epitope-tagged
expression vectors. After 24 h, The cells were serum-starved (1% FBS, 30 min, 37 °C),
washed with cold Hank’s balanced salt solution (HBSS containing 20 mM HEPES, pH 7.2)
and 2% BSA (HBSS/HEPES/BSA), and blocked with normal goat γ-globulin (200 μg/ml,
30 min, 4 °C). For FRAP studies on singly-expressed receptors, the cells were then labeled
successively at 4 °C in HBSS/HEPES/BSA (45 min incubations) with: (i) monovalent
murine Fab’ anti myc tag (myc) or anti HA tag (HA; 40 g/ml), prepared from the
respective IgGs as described by us earlier138; (ii) Alexa 546-Fab’ goat anti mouse (GM;
40 g/ml), prepared from the respective F(ab’)2 as described139. For patch/FRAP studies,
they were labeled by one of two protocols. Protocol 1 employed successive labeling with:
(i) monovalent mouse Fab’ myc (40 μg/ml), alone or together with HA.11 rabbit HA
IgG (20 μg/ml) and (ii) Alexa 546-Fab’ GM (40 μg/ml) alone or together with Alexa 488IgG goat anti rabbit (GR; 20 μg/ml). This protocol results in the HA-tagged receptor
crosslinked and immobilized by IgGs, whereas the myc-tagged receptor, whose lateral
diffusion is then measured by FRAP, is labeled exclusively by monovalent Fab′.
Alternatively, we employed protocol 2 for immobilizing the myc-tagged receptor and
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measuring the lateral diffusion of a co-expressed Fab’-labeled HA-tagged receptor: (i)
monovalent mouse Fab' HA (40 μg/ml) together with chicken IgY myc (20 μg/ml) and
(ii) Cy3-Fab′ donkey anti mouse (DM; 40 μg/ml) together with FITC-IgG donkey anti
chicken (DC; 20 μg/ml). In experiments with inhibin A, the ligand was added after
starvation along with the normal goat -globulin and maintained at the same concentration
throughout the labeling steps and FRAP measurements.
FRAP and patch/FRAP: COS7 cells co-expressing epitope-tagged receptors labeled
fluorescently by anti-tag Fab′ fragments as described above were subjected to FRAP or
patch/FRAP experiments as described140. FRAP studies were conducted at 15 °C, replacing
samples after 20 min to minimize internalization. An argon-ion laser beam (Innova 70C,
Coherent, Santa Clara, CA) was focused through a fluorescence microscope
(Axioimager.D1; Carl Zeiss MicroImaging, Jena, Germany) to a Gaussian spot of 0.77 ±
0.03 μm (Planapochromat 63x/1.4 NA oil-immersion objective). After a brief measurement
at monitoring intensity (528.7 nm, 1 W), a 5 mW pulse (20 ms) bleached 60–75% of the
fluorescence in the illuminated region, and fluorescence recovery was followed by the
monitoring beam. Values of D and Rf were extracted from the FRAP curves by nonlinear
regression analysis, fitting to a lateral diffusion process 140. Patch/FRAP studies were
conducted analogously, except that IgG-mediated cross-linking of epitope-tagged endoglin
preceded the measurement140.
Patient Ascites: Specimens from patients diagnosed with primary ovarian cancer was
collected and banked after informed consent at Duke University Medical Center, with
approval for the study from Duke University’s institutional research ethics board. ELISA’s
were conducted using ELISA for Total inhibin from Ansh labs (#AL-134).
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Public Data Mining: Clinical data and normalized RNA-seq were obtained from
cBioportal141. The ovarian serous cystadenocarcinoma (TCGA, PanCancer Atlas) and
breast invasive carcinoma (TCGA, PanCancer Atlas) were assessed for INHA expression
and hypoxia (Buffa or Winter) scores. INHA expression was plotted against hypoxia score
for each patient for correlation analysis.
IN VIVO ASSAYS. All animal studies and mouse procedures were conducted in
accordance with ethical procedures after approval by UAB’s IACUC prior to study
commencement.
Matrigel Plug Assay: Matrigel plugs were formed using 200L of Matrigel mixed with
50L of HEY conditioned media and injected subcutaneously into the underside of
BALB/c female mice aged 5–6 weeks. For conditioned media, HEY cells were grown until
80% confluence in 24 well plate before media was replaced with fresh full serum media.
Cells were placed in hypoxia chamber for 24hrs and media was collected and concentrated
to 50L Savant SpeedVac SPD1030. Conditioned media was incubated with 2g of either
R1 or IgG overnight before injection. Plugs were harvested 12 days after injection and
hemoglobin content was determined according to Drabkin’s method57.
In vivo subcutaneous tumor growth and permeability analysis: 3x106 HEY cells either
exposed to normoxia or hypoxia (0.2% O2) for 24hrs were subcutaneously injected into
right flank of 6-week-old Ncr Nude mice (Taconic). Tumor volume ((LxW2)/2) was
calculated by caliper measurements every other day starting at day 10 until harvest at day
30. In animals receiving anti-inhibin treatment, R1 (BioCare) was administered IP at
2mg/kg three times weekly. Da Vinci Green diluent (BioCare) was administered as vehicle.
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For measurement of permeability, tumors were harvested between 700-800mm3.
At end point, Rhodamine Dextran 70 000 MW was intravenously injected at 2mg/kg two
hours before euthanasia. Tumors were fixed in 10% NBF and sections were analyzed for
rhodamine-dextran by immunofluorescence on EVOS M7000. Three sections per tumor
were quantified and four images per section were taken. Thresholding was performed in
ImageJ and kept constant for all images. ROUT analysis (Q= 10%) was performed to test
for outliers.
For tumor hypoxia analysis, tumors were harvested at varying sizes between 2001400mm3. Pimonidazole (HydroxyProbe) was injected intravenously at 60mg/kg 1hr
before sacrifice. Tumors were fixed in 10% NBF and sections were analyzed for
pimonidazole adducts using anti-pimonidazole monoclonal antibody.
Immunofluorescence on Tissues: Briefly, formalin fixed, paraffin-embedded tissues from
subcutaneous tumors were deparaffinized by sequential washing with xylene, 100%
ethanol, 90% ethanol, 70% ethanol and distilled water for 10 min each. Antigen retrieval
was performed by boiling tissues in sodium citrate buffer (pH 6.0). Blocking was
performed with Background Punisher. Primary antibodies, anti-pimonidazole (1:50) and
anti-CD-31(1:100), were diluted in Da Vinci Green Diluent and incubated overnight at 4°C
in a humidified chamber followed by AlexaFluor 594 secondary antibody. Nuclei were
stained with DAPI. 10x images were acquired on EVOS M7000 microscope.
Quantitation of CD-31 labeled vessel size and number as well as pimonidazole was
performed in ImageJ. Images were converted to binary and thresholding mask was applied
equally to all images. For CD-31, objects smaller than 25 pixels were removed as were
deemed too small to be vessels. For each image, average vessel size (area) and average
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vessel number was measured. Four images per section and two sections per tumor were
used for quantitation. For pimonidazole, a 10x stitched image comprising the whole tumor
section was used. The total area covered by signal was acquired and divided by total tumor
area to calculate the % hypoxic area for each tumor.
Angiogenesis Proteome Array was performed according to manufacturer’s instruction
(R&D Systems, Table 2.1). Briefly, tissues were homogenized in PBS with 1% TritonX100 and PI cocktail. 200g of protein was used per sample (two samples for shControl and
shINHA tumors each). Pixel intensity was quantified for each dot using ImageStudio
software after background subtraction.
Statistical Analysis: All data are representative of three independent experiments, unless
otherwise described in legends. Statistical analyses were performed using GraphPad Prism
9, with statistical test chosen based on experimental set up and specifically described in the
figure legends. Data are expressed as mean ± SEM. Difference between two groups was
assessed using a two-tailed t-test. Multiple group comparisons were carried by the analysis
of variance (ANOVA) using One or Two-way ANOVA followed by appropriate post-hoc
tests as indicated in Figure legends.

2.3 Expression and secretion of inhibin is regulated by hypoxia in ovarian
cancer cell lines
We and others have previously demonstrated increased expression of inhibin
mRNA and protein in a broad spectrum of cancers leading to increased angiogenesis in
vitro and in vivo impacting metastasis57,78,128. Based on the potential role of inhibins’ in
cancer angiogenesis, we tested the impact of hypoxia, a key regulator of angiogenesis, on
INHA expression. The high grade serous ovarian cancer cell lines HEY and OV90 cells
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were exposed to varying levels of oxygen (control tissue culture conditions (20%), 10%,
5%, 2.5%, 1%, and 0.2% O2) for twenty four hours to evaluate INHA expression and
VEGFA expression (as a positive control142) by semi-quantitative RT-PCR. INHA
expression was significantly elevated in 0.2% O2 (4.9-times) (Figure 2.1Ai) in both HEY
cells and OV90 cells. In OV90 cells, INHA was elevated at 1% (2.7-times) as well, however
not significantly (Figure 2.1Ai). A similar pattern was observed for VEGFA expression
with significant increases in both HEY and OV90 at 0.2% O2 (HEY: 3.8-times and OV90:
4.3times) and at 1% in HEY (2.4-times) (Figure 2.1Aii). HIF-1 stabilization was evaluated
by western blotting to confirm an active hypoxic response that was oxygen tension
dependent (Figure 2.1Aiii). To further test the impact of hypoxia on INHA expression, a
panel of ovarian cancer cell lines representing a broad spectrum of ovarian cancer subtypes,
including HEY, OV90, OVCAR5 of high-grade serous origin, PA1 a teratocarcinoma cell
line of the ovary, and ID8ip2 a mouse ovarian cell like, were grown for twelve or twentyfour hours under either hypoxic conditions (0.2% O2) or normoxic control tissue culture
conditions (17-21%). We find 3-6 times increase in INHA expression across all four cell
lines (HEY: 4-times, OVCAR5: 4.4-times, PA1: 5.28, OV90: 4.8-times, ID8ip2: 4-times,
Figure 2.1Bi). All cell lines showed maximum INHA increases after 24hrs of hypoxia
growth except for OVCAR5 which increased INHA expression within 12hrs under
hypoxia. VEGFA was evaluated side by side as a positive control and representative of the
hypoxia response in all four cell lines and was elevated 2-6-times (HEY: 3.5-times,
OVCAR5: 3.1-times, PA1: 5.18-times, OV90: 2.5-times, ID8ip2: 2-times, Figure 2.1Bii).
The INHA response to hypoxia was also more robust in tumor cells as compared to
endothelial cells (HMEC-1) grown under hypoxia (0.2% O2) for either 12hrs or 24hrs
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(Figure 2.1C) indicating that inhibin increases in response to hypoxia occur more
significantly in tumor cells.
To test if INHA expression remains elevated after re-exposure to oxygen, we first
determined how long HIF-1 protein remained stabilized in cells when returned to normoxic
conditions (reoxygenation) after 24hr exposure to hypoxia. HIF-1 protein began to
decrease 5 minutes after re-exposure to hypoxia (re-oxygenation) and went back to baseline
at 60 minutes in HEY and OV90 cells (Figure 2.1Di). Since we observed HIF-1 levels
return to baseline after 60 minutes, we began our time course for testing INHA expression
after re-oxygenation at one hour. In HEY cells, INHA expression was increased four-times
upon exposure to hypoxia (Figure 2.1Dii). Upon one hour of reoxygenation, INHA
expression decreased significantly in both cell lines and was no longer statistically different
from normoxia grown cells (Figure 2.1Dii). Slight elevation in INHA levels remained,
particularly in OV90 cells for the duration of the time course (Figure 2.1Dii) that did not
however reach statistical significance. Taken together, these data strongly indicate that
inhibin mRNA and protein expression is increased under hypoxia conditions.
INHA translates into the protein inhibin which can be secreted as a free monomer
or can dimerize with INHBA or INHBB to produce dimeric functional inhibin A or inhibin
B126. Thus, total inhibin ELISA, specific to inhibin so as to detect all three inhibin forms,
was used to test if the changes in INHA mRNA resulted in alterations to secreted protein.
We find that conditioned media collected from HEY and OV90 exposed to hypoxia
increased total inhibin protein secretion as well, (4.2-times in HEY and 3.8-times OV90,
Figure 2.2A). These data suggest that INHA mRNA and functional secreted inhibin protein,
is increased by hypoxia.
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Since total inhibin protein, reflecting either inhibin A/B and free inhibin,
increased in response to hypoxia (Figure 2.2B), we evaluated mRNA changes in INHBA
and INHBB subunits in HEY and OV90 cells. While INHA was increased three to fivetimes in response to hypoxia (Figure 2.1Bi), INHBA and INHBB levels were unchanged in
the two cell lines evaluated (Figure 2.2B), indicating that changes in inhibin protein levels
(Figure 2.2A) were largely related to increases in inhibin.

2.4 Inhibin is increased in ovarian cancer spheroids, patients, and
tumor xenografts
To evaluate other pathologically relevant hypoxic conditions pertinent to ovarian
cancer growth and metastasis, we evaluated hypoxia and INHA expression in cells grown
in spheroids under anchorage independence, an environment that is often hypoxic107. PA1
and OVCA420 cells were chosen due to their ability to form spheroids143,144. Cells were
grown on poly-hema coated plates for either 72hrs (PA1) or 48hrs (OVCA420). Under
such anchorage independent conditions (referred to as 3D), where HIF-1 was stabilized
(Figure 2.3Ai), INHA was increased 7.8-times in PA1 and 4.6-times in OVCA420 when
compared to 2D growth conditions in a dish (Figure 2.3Aii).
Previous studies have established that in healthy pre-menopausal women, inhibin
levels cycle across the menstrual cycle reaching a peak of 65.6 pg/mL, while in postmenopausal women, total serum inhibin levels are below 5 pg/mL145. Ovarian cancer
patients are commonly postmenopausal146 and tumor tissues can display higher inhibin
levels57. We thus wanted to assess if the peritoneal ascites fluid of advanced ovarian cancer
patients, which has been shown to be a hypoxic environment108 and contains disseminated
ovarian cancer spheroids105, also displays detectable or elevated inhibin levels. To test if
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inhibin protein is secreted and detectable in clinical ascites, total inhibin ELISA was
performed on a cohort of 25 patient ascites. We find total inhibin levels in the range of 6.7
to 120.53pg/mL in the ascites fluid indicating the presence of inhibin protein in ascites
fluid (Figure 2.3B).
We next evaluated if INHA expression was elevated in vivo with increasing
xenograft tumor size. 5 million HEY cells were subcutaneously implanted and harvested
at varying tumor sizes. Tumors greater than 500mm 3 were found to be hypoxic based on
pimonidazole staining which has a detection threshold of below 10mmHg O 2, or 1.2% O2
(4.8-times, Figure 2.3Ci,ii)147. INHA expression was increased 9.8 times in tumors greater
than 500mm3 as compared to tumors less than 500mm3 (Figure 2.3Di). INHA expression
was also significantly correlated with tumor size (Figure 2.3Dii). To further examine the
potential clinical relevance of inhibin expression in response to hypoxia, we analyzed the
TCGA/PanCancer Atlas patient data set from cBioportal141,148 and obtained hypoxia scores
from two different hypoxia gene signatures (Buffa and Winter)149,150. The signatures
consisted of 51 (Buffa) and 99 (Winter) hypoxia related genes from a large meta-analysis
of breast and head and neck squamous cell cancer that were independently verified for
prognostic value149,150. Using these signatures, inhibin (INHA) expression was
significantly correlated with both hypoxia Buffa (r=0.1961, p=0.0221) and Winter hypoxia
(r=0.223, p=0.009) scores in the ovarian cancer data set (Figure 2.3Ei,ii). Analysis of breast
cancer data revealed a similar trend as INHA expression was significantly correlated
(r=0.2026, p=0.0165) with the Winter hypoxia score (Figure 2.3Eiii). Taken together, these
data strongly indicate that inhibin mRNA and protein expression are increased under
hypoxia conditions in ovarian cancer cell lines, xenograft tumors and in patients.
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2.5 INHA is a direct HIF-1 target under hypoxia
Hypoxia inducible factors (HIFs) are key transcriptional regulators of the hypoxia
adaptive response and increase expression of critical pro-angiogenic genes104. To test
whether HIF proteins are regulators of INHA expression, we first utilized cobalt chloride
(CoCl2), a well characterized chemical stabilizer of HIF’s151. HIF-1 was stabilized in PA1
and OVCAR5 cells treated with 100M of CoCl2 for either 6, 12, or 24 hrs (Figure 2.4Ai).
We find that INHA expression was significantly increased; 10-times in OVCAR5 after
12hrs and 11.5-times in PA1 cells after 24hrs of CoCl2 treatment (Figure 2.4Aii).
Maximum increases in INHA expression with CoCl2 occurred at the same time points as
exposure to hypoxia (12hrs for OVCAR5 and 24hrs for PA1, Figure 2.1Bi). VEGFA, used
as a positive control increased 4.8 and 4.3-times at 12hrs and 2.7 and 3.7-times at 24hrs in
both OVCAR5 and PA1, respectively (Figure 2.4Aii). To test if INHA could be a direct
hypoxia target leading to increased inhibin expression, we evaluated the effect of
reducing the levels of HIF-1β/ARNT which is the binding partner for all HIF’s152. Stable
ARNT knockdown cells were generated in HEY cells (Methods). We find that control HEY
cells increase INHA levels 2.8-times under 0.2% hypoxia (Figure 2.4B). However, shRNA
ARNT lead to a 2.7-times reduction in hypoxia induced increase in INHA mRNA levels
(Figure 2.4B) indicating direct contributions of HIFs to the regulation of inhibin.
To determine the roles of the HIF-1 and HIF-2 heterodimeric transcriptions factors,
that both require ARNT152, in the transcriptional regulation of INHA we used siRNA to
knockdown the levels of HIF-1 and HIF-2 in two ovarian cell lines (OV90 and HEY).
Knockdown of HIF-1 and HIF-2 using siRNAs to each isoform individually or a
combination of siRNAs was confirmed through western blotting (Figure 2.4Ci,ii).
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Knockdown of HIF-1 decreased hypoxia induced INHA expression 2.1 times in HEY and
1.9 times in OV90 compared to siScr (siHIF-1, Figure 2.4Ci,ii). siRNA to HIF-2 did
not result in a significant change in hypoxia induced INHA expression compared to control
(siHIF-2, Figure 2.4Ci,ii). To further test that HIF-1 was the required HIF isoform for
hypoxia induced INHA expression, we utilized a double knockdown of HIF-1 and HIF2. In HEY and OV90 cells the double knockdown resulted in a 2-times and 1.8-times
decrease in INHA expression compared to siScr, respectively (siHIF-1,2, Figure 2.4Ci,ii).
These data suggest that increases in INHA under hypoxia were more significantly impacted
by HIF-1 as compared to HIF-2.
In silico, analysis of the INHA gene, which is located at Chr:2q35 revealed two
hypoxia response element (HRE) consensus sites within 2Kb of the promoter, GGCGTGG
and CGCGTGG, at -144 and -1789 bp from the transcription start site (TSS) (Figure 2.5A)
respectively. These HRE sites conform precisely to the (G/C/T)(A/G)CGTG(G/C)
consensus sequence152. Two hypoxia ancillary sequences (HAS) (CAGGG and CACGG)
were also found directly flanking the proximal HRE sequence at -169 and -173 bp from
the TSS, respectively. One HAS sequence (CACGT) was found flanking the distal HRE
sequence at -1761 bp from TSS (Figure 2.5A). A previously well characterized CREB
binding site (CRE) is designated for reference (Figure 2.5A).
To test direct interactions between HIF-1 and the INHA promoter, chromatin
immunoprecipitation (ChIP) was performed using OVCAR5 and OV90 cells. Primers were
designed to amplify the region including the HRE site closest to the transcription start site
(HRE1) and chromatin shear size optimized accordingly (Methods). We find that exposure
to hypoxia led to a 4-times increase in enrichment of HIF-1 binding to INHA’s HRE site in
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OVCAR5 and 3-times in OV90 (Figure 2.5Bi). The second HRE site is GC rich which lead
to modest amplification. Despite this, a 2-times increase in HIF-1 enrichment at this site in
OV90 cells was observed (Figure 2.5Bii) which was however not statistically significant.
Given the poor enrichment of HIF-1 at the distal promoter site (Figure 2.5Bii), we
next evaluated if the proximal promoter was sufficient to increase INHA levels under
hypoxia and if this was dependent on HIF-1. To achieve this, we made an INHA promoter
driven luciferase reporter construct, containing 547 base pairs of the INHA promoter,
containing the first HRE site (Figure 2.5C, Figure 2.5A). The effect of HIF-1 on INHA
promoter activity, was evaluated in HEK293 cells exposed to hypoxia (0.2% O 2) for 24hrs
and compared to cells under normoxia (Figure 2.5Ci), or in the presence or absence of HIF1 ODD (pcDNA3-HA-HIF1aP402A/P564A) (Figure 2.5Cii) that prevents degradation of
the HIF1 subunit153. We find that in un-transfected or control vector expressing cells
(pcDNA3.1), INHA promoter driven luciferase activity is increased two times in response
to hypoxia (Figure 2.5Ci) that was mimicked by stabilization of HIF-1 (HIF-1 ODD)
under normoxia conditions (Figure 2.5Ci). We also confirmed the requirement of HIF-1
in HEK293 using either control or HIF1/2 siRNAs. HEK293 were exposed to hypoxia
for 24hrs and efficacy of HIF1/2 knockdown was confirmed by immunoblotting (Figure
2.5Di). Notably, siRNA to HIF-1 (siHIF-1) decreased hypoxia induced INHA
expression 1.8-times as compared to scramble controls (siScr; Figure 2.5Dii). However,
siRNA to HIF-2 resulted in a smaller (1.25-times) and non-significant reduction in INHA
expression compared to siScr when exposed to hypoxia (Figure 2.5Dii). These data point
to a central role for HIF-1 in regulating INHA expression under hypoxia.
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INHA has been previously reported to be regulated by other factors particularly the
cAMP response element binding (CREB) family member in multiple systems 5. The CREB
family of transcription factors can act downstream of the hypoxia response154. To thus test
whether cAMP was involved in regulating INHA expression under hypoxia, we utilized
forskolin (Fsk), an activator of cAMP previously shown to induce INHA expression and
the PKA inhibitor H89 previously shown to inhibit forskolin induced INHA expression155.
Treatment of ID8ip2 cells with Fsk increased INHA expression 5.2-times under hypoxia
compared to just 2-times under normoxia (Figure 2.5Ei). This relationship appeared to be
additive and not synergistic as addition of the PKA inhibitor, H89, was not able to reduce
hypoxia induced INHA expression (Figure 2.5Ei). The effect of blocking PKA signaling
under hypoxia was also tested in OV90 cells. Hypoxia increased INHA expression 4.5times however treatment with H89 did not significantly reduce INHA expression under
hypoxia (Figure 2.5Eii). Taken together, these data implicate HIF-1 as being the key
transcriptional factor responsible for increase of INHA in hypoxia.

2.6 Inhibin promotes hypoxia induced angiogenesis and stimulates
endothelial cell migration and vascular permeability
Hypoxia is a key driver of endothelial cell migration and blood vessel permeability
within the tumor leading to alterations in angiogenesis142. To determine the overall
contribution of inhibin to hypoxia induced angiogenesis in vivo, we utilized an in vivo
Matrigel plug assay. Conditioned media (CM) from HEY tumor cells exposed to normoxia
or hypoxia was used to stimulate angiogenesis into the plugs, and a well-established antiinhibin antibody, R1 (recognizing the junction between the N region, and C region)156
was used to block inhibin in the CM with IgG as a control. We find that CM from hypoxia
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grown cells increased hemoglobin in the plugs 2.9-times compared to CM from normoxia
grown cells (Figure 2.6Ai-ii). Anti-inhibin in the hypoxic CM fully reduced the
hemoglobin content in the plug (2.1-times suppression, Figure 2.6Ai-ii) indicating that
inhibin is required for hypoxia induced blood vessel formation in vivo.
Since blood vessel flow is an indication of endothelial cell functionality 157, we
sought to define the specific effects of increased inhibin on hypoxia induced endothelial
cell biology, specifically endothelial cell chemotaxis and vascular permeability. To
determine the impact on endothelial chemotaxis to hypoxic CM, CM from either hypoxia
(24 hrs, 0.2% O2) or normoxia grown OV90 or HEY cells were used as a chemoattractant
to measure migration of human microvascular endothelial cells (HMEC-1; Figure 2.6B).
Two anti-inhibin antibodies, R1 and a second well established antibody PO23
(recognizing the C-terminus of the C region)156, were used with IgG controls to test the
effect of blocking/sequestering hypoxia produced inhibin. We find that CM from hypoxia
grown tumor cells significantly increased migration of endothelial cells (IgG, Figure 2.6B)
and incubation of hypoxic CM with anti-inhibin R1 significantly suppressed hypoxia
induced endothelial migration (2.1 and 1.6-times for OV90 and HEY conditioned media
respectively, Figure 2.6Bi,ii). Anti-inhibin PO23 was also able to significantly suppress
CM stimulated endothelial migration (1.5 and 1.75-times for OV90 and HEY CM,
respectively, Figure 2.6Bi-ii). Similar to the effects of hypoxic CM, recombinant inhibin
A was also able to stimulate HMEC-1 migration to similar extents as VEGF A at equimolar
amounts (Figure 2.6Biii).
We next evaluated the effect of CM from hypoxic tumor cells on changes to
permeability across an endothelial monolayer using a trans-well permeability assay that
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measures solute (FITC-dextran) flux across endothelial monolayers. Permeability was
monitored across a four-hour time course and CM from hypoxic tumor cells was used to
induce permeability across the HMEC-1 monolayer. Effect of inhibin in the CM was
evaluated either in the presence of anti-inhibin (PO23 and R1) or IgG control (Figure
2.6Ci-ii). We find that both inhibin antibodies (R1 and PO23) significantly decreased
solute flux induced by hypoxic CM from two tumor cell lines, albeit with moderate
differences in the kinetics and time to inhibition (Figure 2.6Ci-ii). Specifically, significant
inhibition of permeability was seen beginning at two hours for CM treated with PO23 and
three hours for R1. PO23 was moderately more effective than R1 as it effectively reduced
permeability within 1 hour (Figure 2.6Ci-ii). Recombinant inhibin was also able to induce
endothelial cell permeability to similar extents as LPS (Figure 2.6D), an established
permeability inducing factor108. Since perturbations to the endothelial barrier are critical to
invasion and extravasation of cancer cells during metastasis158, we tested whether inhibin
induced vascular permeability facilitates tumor cell extravasation. To test this, we used a
trans-endothelial cell migration assay to mimic the process. HEY tumor cells infected with
GFP adenovirus to distinguish them from migrated non-GFP endothelial cells were plated
on top of a non-GFP endothelial cell monolayer that was then either pre-treated with 1nM
inhibin A for 4 hours or left untreated. We find that HEY GFP tumor cells, were 2.9-times
more invasive across the inhibin treated monolayer than untreated conditions (Figure
2.6Eii-iii). All together, these data implicate inhibin as a robust contributor to hypoxia
mediated angiogenesis, vascular permeability and thereby tumor cell extravasation across
the vascular endothelium.
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2.7 Inhibin promotes vascular permeability through increased VEcadherin trafficking.
Endothelial permeability is regulated through changes in junctional proteins which
are maintained through contacts with the actin cytoskeleton159. VE-cadherin is a critical
junctional protein involved in regulating endothelial cell permeability159. To delineate the
mechanism of inhibin’s effects on vascular permeability, we first evaluated the effect of
inhibin on endothelial cell junctions and the actin cytoskeleton through immunofluorescent
staining of VE-cadherin and actin (Figure 2.7A). Examination of the actin cytoskeleton
revealed significant contractile actin staining, with a significant increase in stress fiber
formation after 30 minutes of inhibin A treatment (two times increase, Figure 2.7Ai-ii).
VEGF A treatment was used as a comparison that also led to similar changes in actin stress
fiber formation (Figure 2.7A). VE-cadherin localization also appeared to be reduced
qualitatively at the cell-cell junctions after 30 minutes of inhibin treatment as compared to
untreated cells, suggestive of perturbation of the endothelial cell barrier at the level of the
cytoskeleton (Figure 2.7A). Loss of VE-cadherin at the cell junctions was also observed in
VEGF A treated cells (Figure 2.7A). However, total VE-cadherin levels were unchanged
in response to inhibin as evaluated over a time course of 60 minutes (Figure 2.7B)
indicating no change in the total pool of VE-cadherin in response to inhibin A. Actin
contractility and stress fiber assembly is regulated through phosphorylation of myosin light
chain (MLC)159. In accordance, we find that phosphorylation of MLC-2 (Ser19) increased
within 5 minutes of inhibin A treatment and was sustained across a 60-minute time course
(Figure 2.7Ci,ii).
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Based on the qualitative changes in VE-cadherin in response to inhibin A treatment
(Figure 2.7A), we tested whether alterations in VE-cadherin at the cell-cell junctions were
due to inhibin induced VE-cadherin internalization. To determine this, HMEC-1 membrane
localized VE-cadherin was labeled at 4C with an anti-VE-cadherin antibody recognizing
the extra-cellular domain. HMEC-1 cells were washed with acid to remove membrane
bound anti-VE-cadherin leaving only any internalized VE-cadherin that may have been
labeled at 4C prior to treatment with inhibin A or VEGF A (Figure 2.8A). Stripping of
cell surface VE-cadherin was verified by cell surface immunostaining of VE-cadherin with
little to no internalized VE-cadherin detected (Figure 2.8Bi,iii). Cells were then either left
untreated or treated for 30 minutes with inhibin A at 37oC and VE-cadherin evaluated by
immunofluorescence (Figure 2.8Bii). We find that inhibin A increased the internalized VEcadherin pool compared to untreated cells 1.4-times (Figure 2.8Civ) and to similar extents
as VEGF A (1.6-times, Figure 2.8Civ). These results indicate that inhibin induces rapid
changes in the actin cytoskeleton and trafficking of VE-cadherin from the cell junctions of
endothelial cells.

2.8 Inhibin’s effects on vascular permeability are mediated by ALK1
and CD105/endoglin that form a stable complex at the cell surface in
response to inhibin
Previously, we demonstrated that inhibin’s effects on angiogenesis and endothelial
cell signaling were dependent on the TGF receptors ALK1 and endoglin57. To evaluate
if ALK1 and endoglin are required for inhibin’s influence on vascular permeability, we
treated HMEC-1 cells with TRC105, a humanized endoglin monoclonal antibody

160

, or

with ALK1-Fc, a human chimeric ALK1 protein161. At four hours, treatment with (i)
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TRC105 and (ii) ALK1-Fc decreased inhibin A induced permeability by 2.2 and 1.5-times,
respectively (Figure 2.9A) indicating both ALK1 and endoglin are required for inhibin’s
effects on endothelial cell permeability.
We next evaluated if internalization of VE-cadherin by inhibin was dependent on
endoglin using mouse embryonic endothelial cells (MEEC) that are either wild type (WT)
or null for endoglin expression51 (Figure 2.9B). Cell surface biotinylation of VE-cadherin
was used to quantitatively assess VE-cadherin internalization. Towards this, cell surface
proteins were labeled with Sulfo-NH-SS biotin and allowed to internalize for 30 minutes
at 37C in the presence or absence of inhibin followed by stripping of cell surface biotin,
immunoprecipitation with neutravidin resin and immunoblotting to detect internalized
biotin labeled VE-cadherin (Figure 2.9C). Treatment with inhibin A increased internalized
VE-cadherin 1.9-times in MEEC WT compared to control (Figure 2.9Di), similar to extents
seen by immunofluorescence in HMEC-1 cells (Figure 2.9B). However, in the absence of
endoglin in MEEC ENG-/- cells inhibin A did not change the internalized VE-cadherin
pool (Figure 2.9Dii). This data indicates that endoglin is essential for inhibins effects on
VE-cadherin.
Based on the significant dependency of inhibin’s effects on endothelial cell
permeability and VE-cadherin internalization on endoglin and ALK1 respectively (Figure
2.10A,D), we evaluated biophysically, in a sensitive and quantitative manner, the extent of
the endoglin-ALK1 interaction in response to inhibin. We utilized a patch/FRAP
(fluorescence recovery after photobleaching) methodology to measure interactions
between endoglin and ALK1 at the surface of live cells. This method differentiates between
stable and transient interactions as described in detail previously162. Herein, one receptor
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carrying an extracellular epitope tag is patched and immobilized through cross-linking with
a double layer of IgGs. The effects of this immobilization on the lateral diffusion of a coexpressed, differently tagged receptor labeled exclusively with Fab’ fragments are then
measured by FRAP (Methods). Stable complex formation between the two co-expressed
receptors (complex lifetimes longer than the characteristic FRAP fluorescence recovery
time) reduces the mobile fraction (Rf) of the Fab’-labeled receptor, since bleached Fab’labeled receptors associated with immobilized receptors do not appreciably dissociate from
the immobile patches during the FRAP measurement. On the other hand, transient
complexes (short complex lifetimes) would reduce the apparent lateral diffusion coefficient
(D), since each Fab’-labeled receptor molecule can undergo multiple associationdissociation cycles during the FRAP measurement162. For these studies, COS7 cells were
transfected with myc-ALK1, HA-endoglin or co-transfected with both, and subjected to
patch/FRAP experiments in the absence or presence of 4 nM of inhibin A (Figure 2.10A).
Figure 2.10Ai-iii depict representative FRAP curves showing the lateral diffusion of mycALK1 (Figure 2.10Ai), IgG-crosslinked and immobilized HA-endoglin (Figure 2.10Aii),
and myc-ALK1 co-transfected with HA-endoglin followed by IgG cross-linking of HAendoglin in the presence of inhibin (Figure 2.10Aiii). Average values derived from multiple
independent experiments are shown in (Rf in Figure 2.10Av, D values Figure 2.10ACv).
Singly expressed myc-ALK1 had lateral mobility resembling other TGF- superfamily
receptors140, which was insensitive to inhibin treatment Figure 2.10ACi ,iv).
Immobilization of HA-endoglin (Figure 2.10Aii,iv) reduced Rf of myc-ALK1 by about
45%, and the presence of inhibin increased this reduction significantly (from 45% to 70%
reduction) (Figure 2.10Aiii,iv). Under all these conditions, the lateral diffusion coefficient
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(D) of myc-ALK1 was not significantly affected (Figure 2.10ACv), indicating that
endoglin and ALK1 form stable complexes at the plasma membrane which are enhanced
and stabilized by inhibin.
Previous studies indicate that inhibin may bind to ALK454, an established Type I
receptor for the Activin family of proteins5. We thus employed patch/FRAP to determine
the interactions between endoglin and ALK4 and to examine whether inhibin A enhanced
these interactions. To this end, we expressed HA-ALK4, myc-endoglin or both in COS7
cells, and subjected them to patch/FRAP studies on the lateral diffusion of HA-ALK4
without and with IgG cross-linking of myc-endoglin, and with or without inhibin A. In the
absence of inhibin A, endoglin and ALK4 exhibited significant stable interactions, as
demonstrated by the reduction in Rf of HA-ALK4 upon immobilization of myc-endoglin
(40% reduction in Rf, with no effect on the D value) (Figure 2.10Bi-ii). However, in
contrast to the observations with endoglin-ALK1 complexes, the interactions between
endoglin and ALK4 were weakened in the presence of inhibin A (the reduction in Rf
decreased to 20%) (Figure 2.10Bi). Taken together, these results indicate that inhibin shifts
the balance of endoglin complexes from interactions with ALK4 to interactions with
ALK1, both of which (endoglin and ALK1) are required for inhibin mediated vascular
permeability.

2.9 Inhibin promotes hypoxia induced tumor growth in vivo through
alterations in permeability and angiogenesis
The significance of hypoxia in ovarian cancer is well documented and we
previously demonstrated increased ascites accumulation in tumor bearing mice in the
presence of inhibin57. To precisely define the contribution of inhibin to hypoxia induced
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tumor growth and angiogenesis, we first evaluated the effects of pre-exposure to hypoxia
on tumor growth in a subcutaneous model in vivo, a model that allows for quantitative
analysis of the vasculature in tumors163. HEY pLKO.1 control vector (shControl) cells were
pre-exposed to hypoxia (0.2% O2) for 24hrs or kept under normoxia followed by injection
into the right flank of Ncr nude mice. Tumors were measured throughout and harvested
after 30 days (n=10 mice). HEY cells pre-exposed to hypoxia produced rapid growing
tumors compared to those that originated from normoxia grown cells (Figure 2.11A, purple
versus black line). In parallel, we utilized two methods to perturb inhibin: 1) shRNA
knockdown of INHA in HEY cells (Figure 2.11Bi) and 2) intraperitoneal administration of
anti-inhibin antibody (R1). R1 is a human antibody156 and consistent with this no overall
toxicity was noted in pilot toxicity studies that utilized daily injections of R1 (Figure
2.11C). shINHA cells exposed to hypoxia maintained their knockdown to INHA at the end
of the study (Figure 2.11Bii) and produced tumors with significantly slower growth rates
than shControl hypoxia tumors (Figure 2.11A, blue versus black lines). In complementary
findings, hypoxia exposed tumor cells had significantly reduced tumor growth upon
receiving treatment with the R1 antibody when compared to tumors in mice that received
vehicle only (Figure 2.11A, red versus blue line, n=6 for R1 treated mice). The group
receiving anti-inhibin (R1) grew at a similar rate as the shINHA hypoxia tumors (Figure
2.11A, red versus blue line). In mice with shINHA tumors, treatment with R1 further
reduced tumor growth albeit moderately compared to vehicle shINHA (Figure 2.11A, blue
versus green line). These data indicate that perturbation of inhibin through shRNA
targeting, and anti-inhibin antibody treatment reduces tumor growth.
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Next, we sought to evaluate the effect of hypoxia induced inhibin on angiogenesis
within tumor xenografts. To rule out whether the reduction in tumor growth in shINHA
cells was due to slower proliferation of tumor cells, growth rate of HEY shINHA and HEY
shControl was evaluated in culture under hypoxia for 3 days. No significant change was
observed (Figure 2.12A) suggesting that the major effect of inhibin on tumor growth are
likely through effects on the tumor vasculature due to the effects of hypoxia regulated
inhibin on angiogenesis and vascular permeability in vitro (Figure 2.6).
Next, we sought to determine the effect of shINHA on the angiogenic cytokine
profile of the tumors from Figure 2.11A using a proteome array of 55 different human
angiogenesis targets. We find that the most up-regulated proteins in control tumors
compared to shINHA tumors were a subset of pro-angiogenic cytokines IL8 (2.5-times)
and EGF (2.1-times) (Figure 2.12Bi) indicating a proangiogenic profile of the tumor cells
in the presence of inhibin. In contrast, the shINHA hypoxia tumors showed increases in
proteins including ADAMTS-1 (1.6-times) and Pentraxin-3 (1.3-times), indicating an antiangiogenic profile in shINHA tumor cells as both have been demonstrated to be antiangiogenic164,165. Activin A and endoglin were also found to be elevated in shINHA tumors
(Figure 2.12Bi). To complement the human tumor array, we analyzed changes in the mouse
angiogenic proteome as well to delineate any host differences in response to shControl and
shINHA tumor cells. We find that host cells also upregulated significantly more proangiogenic proteins, including CXCL16166, PIGF-2167, and NOV168 in shControl tumors
compared to shINHA tumors (Figure 2.12Bii). Taken together, these data suggest that
altering inhibin in the tumors results in a change in the balance of angiogenic factors
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leading to a significant reduction in pro-angiogenic factors and slower overall tumor
growth.
We thus determined the effect of inhibin on the tumor vasculature and associated
permeability changes as a contributing factor to the altered tumor growth in shINHA and
antibody treated hypoxia tumors (Figure 2.12A). To this end, HEY shControl or shINHA
cells pre-exposed to hypoxia for 24hrs were injected subcutaneously into the right flank of
Ncr nude mice (n=4 mice) and tumors in all groups were harvested upon reaching 700850mm3 (Figure 2.12Ci) to eliminate any tumor size effects on angiogenesis. These tumors
(Figure 2.12Ci) were evaluated for changes in vascular permeability by visualization of a
rhodamine-dextran dye that leaks from the blood vessels into the tumors when
administered into mice prior to sacrifice. We find that rhodamine-dextran was present at
5.5-times higher levels in shControl tumors compared to shINHA tumors indicating higher
vascular permeability within the tumors in the presence of inhibin (Figure 2.12Cii-iii). To
further characterize the differences in the vasculature between shControl and shINHA
tumors, blood vessels were stained with CD-31 to evaluate vessel number and size (Figure
2.12D). We find an increase in the total number of blood vessels in shControl tumors
compared to shINHA tumors (Figure 2.12D i,iii). Quantitation of the size of the vessels
revealed significantly smaller vessels in shControl tumors as compared to the shINHA
tumors (Figure 2.12Dii,iii). These data together demonstrate that reducing inhibin in the
tumor decreases vascular leakiness, alters vessel size and numbers and promotes more
normalized vasculature in the tumors.
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2.10 Discussion
Hypoxia significantly impacts several aspects of tumor progression by regulating
pathways that can be targeted for cancer management, particularly angiogenic
mechanisms. We have for the first time identified inhibins’, that are well established
biomarkers for ovarian and other cancers and a member of the TGF superfamily, to be
targets of the hypoxic response. We significantly extended our previous findings 57 to
demonstrate that hypoxia induced tumor growth, angiogenesis and vascular leakiness is
accompanied with, and dependent on inhibin levels in cells and tumors, and relevant to the
ovarian cancer patient population. In keeping with this, hypoxia induced tumor growth can
be suppressed by treatment with a selective inhibin antibody that leads to a shift in the
angiogenic balance in tumors. We also provide mechanistic evidence for the involvement
of ALK1 and CD105/endoglin in inhibin’s effects on permeability via increased VEcadherin internalization.

Due to the lack of systemic inhibin expression in post-

menopausal women, establishing the therapeutic significance of targeting inhibin in this
patient population may be particularly beneficial to evade systemic side effects seen with
targeting other hypoxia associated angiogenic pathways.
Significant information exists on the cycling levels of inhibins’ in premenopausal
women, the decline of inhibin during perimenopause, and as a marker whose decline
defines the onset of menopause leading to complete absence of inhibin in normal postmenopausal women127. Contrastingly, several studies have reported elevated levels of
Inhibin in a subset of cancers73,77,78,128. Our studies shed light on the potential mechanisms
leading to elevated inhibin. We also find that total inhibin is elevated in the ascites fluid of
patients with ovarian cancer, a hypoxic environment that aids in dissemination of shed

46

ovarian cancer spheroids105,108 (Figure 2.3). Serum inhibin and CA125 levels are both
markers for ovarian cancer66,128 and were also positively correlated with each other in this
patient ascites (Figure 2.13). Menopause status was unknown in these patients however the
median age of the cohort was 62 and only two patients were below 50 years of age (Figure
2.13). INHA expression and hypoxia are also correlated through a hypoxia gene score
(Figure 2.3). Supporting our hypothesis that inhibin is regulated by hypoxia, we also found
that exposure of ovarian cancer cells to hypoxia increased INHA expression and inhibin
secretion (Figure 2.1, 2.2). Surprisingly, we did not note consistent and statistically
significant increases in the activin subunits, INHBA or INHBB which only appeared to be
moderately elevated (Figure 2.2) indicating that increased secretion levels were driven by
inhibin. Previous reports indicate activin, specifically INHBA, increases in response to
hypoxia in endothelial cells169. However, here the increase in INHA levels in endothelial
cells in response to hypoxia was only moderate as compared to in tumor cells (Figure 2.1)
suggesting a potential competition in the tumor microenvironment between activin and
inhibin. The inhibin ELISA used here does not detect dimeric or free activin, as it is specific
to inhibin and detects all forms of inhibin, namely inhibin A/B and free alpha subunit.
Hence, a hypoxia dependent increase in the alpha subunit (INHA), in the absence of a
change in activin mRNA levels (Figure 2.2), could potentially shift the dimerization of the
beta subunits (INHBA/INHBB) from activin homodimers to inhibin heterodimers and
remains to be determined.
Evidence of HIF-1 dependency was observed when hypoxia exposed cells were reexposed to oxygen (re-oxygenation). HIF-1 levels returned to near baseline levels after one
hour which corresponded with INHA expression decreasing to levels not significantly
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different than baseline normoxic levels (Figure 2.1Dii). We did observe elevated, although
non-significant, INHA in OV90 after 1hr of reoxygenation which could be attributed to
mRNA turnover mechanisms. Mechanistically, we find through knockdown studies and
ChIP studies that INHA expression is likely regulated through the HIF-1 transcription
factor binding directly to the INHA promoter (Figure 2.4, 2.5). Our findings on a hypoxia
response in a pathological condition as seen here, is consistent with a previous report
demonstrating that FSH can drive INHA expression in granulosa cells dependent on HIF-1
in what appeared to be in an indirect manner170. Intriguingly, evidence for INHA regulation
by hypoxia, specifically dependent on HIF isoforms, has been demonstrated in
cytotrophoblasts171. Here we present detailed evidence of regulation by HIF-1, with HIF1
interacting at INHA’s promoter under hypoxia (Figure 2.5). cAMP and PKA can be
activated in response to hypoxia as well. However, the PKA inhibitor, H89, was not able
to reduce hypoxia induced INHA expression indicating that cAMP may not be involved in
the hypoxia transcriptional regulation of INHA (Figure 2.5). This does not preclude a role
for cAMP-PKA in the regulation of INHA as it is well established that the cAMP-PKA
signaling axis enhances tumorigenesis in ovarian cancer172. As the effect of forskolin was
additive on INHA expression, cAMP and PKA could represent an alternative or additive
mechanism of regulation of INHA in ovarian cancer.
In prostate and adrenocortical cancers reports of both increased and decreased
inhibin levels have been reported76,77,79. In adrenocortical tumors with lower INHA levels,
methylation of the INHA promoter was reported to occur at the CpG island within the
proximal HRE site that we identified, suggesting potential roles for epigenetic regulation
of INHA as well79. HIF transcription factors have reduced binding to methylated hypoxia
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response elements173. To this end, it is possible that not all cell lines will increase inhibin
expression in response to hypoxia. If this is the case, methylation of INHA’ s promoter may
play a role making further understanding of the regulation of INHA expression, particularly
in patients necessary in the future.
Previously we also demonstrated inhibin’s effects broadly on angiogenesis 57. Here,
we sought to define more precisely the outcomes of inhibin’s effects on angiogenesis,
specifically in the context of hypoxia. Using recombinant inhibin and antibodies to the
alpha subunit of inhibin, we find novel roles for inhibin as a permeability inducing factor
with implications for tumor cell extravasation (Figure 2.6). Inhibin induced permeability
was dependent on ALK1 and endoglin (Figure 2.9). The VE-cadherin dependent
mechanism of permeability observed by us (Figure 2.7, 2.8) is consistent with prior
findings on the effects of other TGF family members’ roles in promoting vascular
permeability, specifically BMP6136. BMP6 induced vascular permeability was mediated
through the Type 1 receptor ALK2136, whereas we expect the Type 1 receptor ALK1 to be
more critical for inhibin induced vascular permeability. Interestingly, inhibin strongly
increased the stable interaction between ALK1 and endoglin (Figure 2.10), in line with our
observation that both endoglin and ALK1 are required for permeability, and endoglin being
critical for VE-cadherin internalization (Figure 2.9). These findings have broad
implications for other TGF family members that may regulate permeability dependent on
Type 1 receptors. The patch/FRAP studies (Figure 2.10) support our current and previous
findings57. Although there are some reports suggesting that inhibin can bind to ALK4 54,
our findings show that inhibin does not enhance endoglin-ALK4 complex formation but
rather weakens it (Figure 2.10). We have previously demonstrated that endothelial cells
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such as HMEC-1 express very little ALK4 compared to ALK157, supporting the idea that
inhibin acts in endothelial cells preferentially via ALK1 in line with a potential
physiological relevance of inhibin-mediated increase in endoglin-ALK1 interactions.
However, these findings in endothelial cells do not contradict the current understanding of
inhibin’s function in non-endothelial cells, which may express more ALK4 than ALK1.
These findings also do not allow us to conclude whether the ALK1-endoglin complex,
which is enhanced by the binding of inhibin, is signaling or kinase competent, as nonsignaling receptor complexes may exist and impact signaling in an indirect manner. Such
complexes were previously reported in the context of activin and ALK2 174,175 and need
further examination for inhibins.
Targeting inhibin through shRNA knockdown and antibody treatment was found
to be an effective anti-angiogenic strategy leading to reduced vascular permeability
increased blood vessel size but fewer number of vessels and a likely more normalized
vasculature (Figure 2.12). Interestingly, in our analysis of the angiogenic proteome of HEY
tumors, permeability promoting cytokines, EGF, IL-8, and DPP4 were significantly lower
in shINHA tumors which were less permeable as compared to shControl tumors (Figure
2.12). Interestingly, the shINHA tumor cells produced more activin and endoglin compared
to shControl tumors (Figure 2.12). Increased activin fits the profile of the shINHA tumors
expressing more anti-angiogenic proteins as activin has been shown to inhibit
angiogenesis123 which could also be a result of decreased inhibin leading to a shift in the
balance to increased dimerization of INHBA/B and thereby activin levels. Similarly,
increases in tumor cell endoglin levels in shINHA tumors in vivo may reflect compensatory
responses to changes in inhibin expression consistent with recent reports on endoglin
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expression changes in ovarian cancers176. Whether these changes impact metastasis and
angiogenesis and are directly related to changes in inhibin levels in patients remains to be
examined. Which of these altered proteins contributes the most to the either pro or antiangiogenic tumor microenvironment remains to be determined as we unravel new roles for
inhibins. In the mouse host cells where inhibin is likely to interact with endoglin from the
endothelia to affect angiogenesis, endoglin levels were slightly higher in shControl
receiving hosts that had more vessels compared to shINHA (Figure 2.12). These findings
also suggest that blocking inhibin could shift the balance between pro and anti-angiogenic
genes.
We also demonstrate for the first time that anti-inhibin in a therapeutic regimen can
reduce tumor growth in vivo (Figure 2.11). The subcutaneous model utilized does not
induce ascites formation, unlike the intraperitoneal model used previously, where mice
with shINHA tumors produced less ascites than those with shControl tumors 57. However,
this model was chosen as it better allows for evaluation of the vasculature in vivo and short
exposure to hypoxia leads to increased tumor growth as seen here (Figure 2.11) and as seen
in other models as well177,178. Our findings that inhibin is elevated in patient ascites (Figure
2.3) supports the idea that inhibin may promote ascites formation, likely through increased
vascular permeability. The effectiveness of anti-angiogenic therapies is attributed to
increased vascular normalization resulting in reduced intra-tumoral hypoxia, perfused and
functional vessels that improve delivery of other chemotherapeutics and enhanced immune
response179. Further studies utilizing intraperitoneal or intrabursal models that present
additional steps of disease progression and metastasis are warranted to evaluate hypoxia
and anti- inhibin approaches therein. Resistance to current anti-angiogenic therapies is also
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common and inhibin A levels have been reported to be increased in patients non-responsive
to anti-angiogenic therapy180 (combination of TRC105 and Bevacizumab) indicating
inhibin as a potential alternative mechanism of angiogenesis in tumors resistant to other
anti-angiogenic therapies. Further studies exploring the impact of anti-inhibin therapy on
the effectiveness of chemotherapeutics and anti-tumor immune response as well is most
certainly warranted.
In conclusion, our study shows that targeting inhibin is an effective anti-angiogenic
strategy. We demonstrate for the first time a contextual mechanism for the regulation of
inhibin directly driven by hypoxia and HIF-1 and fully define inhibin’s contributions to
hypoxia induced angiogenesis. Based on our findings and the previously known
physiological functions of inhibin, we speculate that targeting inhibin may have potential
improved therapeutic value in post-menopausal cancers including a significant percentage
of ovarian cancers.
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Table 2.1. Key Resource Table
RESOURCE

SOURCE

IDENTIFIER

Cell Lines
HMEC-1

ATCC

CRL-3243

HEK293

ATCC

CRL-1573

OV-90

ATCC

CRL-11732

OVCAR-5

NCI-60

N/A

PA1

ATCC

CRL-1572

SKOV3

NCI-60

N/A

OVCA420

Susan Murphy

N/A

ID8ip2Luc

Jill Slack-Davis

N/A

HEY

Susan Murphy

N/A

MEEC WT/ENG -/-

Michelle Letarte

N/A

COS7

ATCC

CRL-1651

Antibodies
p-MLC2

Cell Signaling Technologies

#3671S, AB_330248

HIF-1

Cell Signaling Technologies

#14179,
AB_2622225

HIF-1 (ChIP grade)

Cell Signaling Technologies

#3716, AB_2116962

HIF-2

Cell Signaling Technologies

#59973,
AB_2799579

Normal Rabbit IgG

Cell Signaling Technologies
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#2729, AB_1031062

CD-31

Cell Signaling Technologies

#77699,
AB_2722705

Vinculin

Santa Cruz

Sc-73264,
AB_1131292

Inhibin (R1)

Biocare Medical

SKU171

Anti-inhibin PO23

Oxford Brookes University

Anti-inhibin R1

Oxford Brookes University

AB_2857371

TRC-105

Tracon Pharmaceuticals

#754227

VE-cadherin (for IF)

BD BioSciences

#610252,
AB_2276073

Goat -globulin (NGG)

Jackson ImmunoResearch

#005-000-002,
AB_2336984

Murine IgG anti-myc tag, BioLegend

#626802,

9E10

AB_2148451

Chicken IgY anti-myc tag

Merck Millipore

#AB3252,
AB_2235702

Rabbit IgG anti HA tag, BioLegend

#902302,

HA.11

AB_2565019

Murine IgG anti-HA tag, Roche Diagnostics

#11666606001,

12CA5

AB_514506

Alexa 488-goat IgG anti Invitrogen-Molecular Probes

#R37116,

rabbit IgG

AB_2556544
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Alexa 546-goat (Fab’)2 anti Invitrogen-Molecular Probes

#A-11018,

mouse IgG

AB_2534085

Alexa 488-goat (Fab’)2 anti Invitrogen-Molecular Probes

#A-11070,

rabbit IgG

AB_142134

FITC-donkey

IgG

anti Jackson ImmunoResearch

chicken IgY

#703-095-155,
AB_2340356

(Fab’)2

Cy3-donkey

anti Jackson ImmunoResearch

mouse IgG

#

715-166-150,

AB_2340816
Reagent

Cobalt Chloride (CoCl2)

VWR

#IC19510725

Recombinant inhibin A

R&D Systems

#8506-AB

Recombinant VEGF A

R&D Systems

293-VE-010

ALK1-Fc

R&D Systems

#370-AL

Inhibin ELISA

Ansh Labs

#AL-134

DynaBeads

Thermo Fisher

#10003D

Lipofectamine 3000

Thermo Fisher

#L3000001

TransIT-LT1 Mir2300

Mirus Bio

#MIR 2305

RNAiMax

Thermo Fisher

#13778030

Rhodamine Dextran 70,000 Thermo Fisher

#D1841

MW
FITC-Dextran 30,000 MW
EZ-Link

Thermo Fisher

#D3306

Sulfo-NHS-SS- Thermo Fisher

#21331

Biotin
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Neutravidin Resin

Thermo Fisher

iScript Reverse Transcription BioRad

#29200
#1708841

Supermix
iTaq Universal SYBR Green Biorad

#1725125

Supermix
Dual

Luciferase

Assay Promega

#E1910

System
Matri-gel

Corning

#354230

Fibronectin

Cultrex

#342000101

Mach4 Universal Detection BioCare

# M4U534

Kit
Background Punisher

BioCare

#BP974

Da Vinci Green Diluent

BioCare

#PD900

3,3′-diaminobenzidine

BioCare

#BDB2004

Actin-Phalloidin

Cytoskelton, Inc

#PHDN1

T4 DNA Ligase

NEB

M0202S

HydroxyProbe Kit

HydroxyProbe, Inc

HP1-XXX

(DAB)

Plasmids, siRNA, Lentivirus
pcDNA3-HA-

Will Kaelin, Addgene

#18955

pHIV-Luc-ZsGreen

Brian Welm, Addgene

#39196

pGL4.10

Promega

9PIE665

HIF1aP402A/P564A153
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pGL4.10 INHA

In house

N/A

PCDNA3.1

Thermo Fisher

#V79020

shINHA

Sigma Aldrich

TRCN0000063904

shARNT

Sigma Aldrich

TRCN0000003818

siENG

Dharmacon

#L-011026-00-0005

siHIF-1

Dharmacon

J-004018-07-0002

siHIF-2

Dharmacon

#-004814-06-002

pCMV6

Origene

#SC108895

Other
3M trans-well filter

Greiner Bio-One

#662630

8M trans-well filter

Greiner Bio-One

#662630

PureLink PCR Purification Invitrogen

#K310002

Kit
Amicon Ultra Centirfugal EMD Millipore

UFC501024

Filter
Proteome Profiler Human

R&D Systems

#ARY007

R&D Systems

#ARY015

Angiogenesis Array Kit
Proteome Profiler Mouse
Angiogenesis Array Kit
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Table 2.2. Lentiviral and siRNA sequences
Target

Source

Identifier

Target Sequence

shINHA

Sigma Aldrich

TRCN0000063904

CCTCGGATGGAGGTTACTCTT

shARNT

Sigma Aldrich

TRCN0000003818

CATTGTCCAGAGGGCTATTAA

siHIF-1

Dharmacon

J-004018-07-0002

GAACAAAUACAUGGGAUUA

siHIF-1

Dharmacon

J-004018-08-0002

AGAAUGAAGUGUACCCUA

siHIF-2

Dharmacon

J-004814-06-0002

GGCAGCACCUCACAUUUGA

siHIF-2

Dharmacon

J-004814-07-0002

GAGCGCAAAUGUACCCAAU

58

Table 2.3. List of primers.
Primers

Forward

Reverse

RPL13A

AGATGGCGGAGGTGCAG

GGCCCAGCAGTACCTGTTTA

INHA

CGCTCAACTCCCCTGATGTC

GGGTACACGATCCACCGTTC

VEGF

CGCCAACCACAACATGCAG

GCTCCACGAAGGATGCCAC

ENG

GCCATCCAATCGAGACCCTG

TGATTGTTGGACTCCTCAGTG

Human

TGFBR3 CGTCAGGAGGCACACACTTA

CACATTTGACAGACAGGGCAAT

INHBA

GAACGGGTATGTGGAGATAGAG TGTTCCTGACTCGGCAAA

INHBB

GCGCGTTTCCGAAATCATCA

AGGTTCTGGTTGCCTTCGTT

ARNT

TGACTCCTGTTTTGAACCAGC

CTGCTCACGAAGTTTATCCACAT

RPL13A

CAAGGTTGTTCGGCTGAAGC

GCTGTCACTGCCTGGTACTT

INHA

AGGAAGATGTCTCCCAGGCT

GTTGGGATGGCCGGAATACA

VEGF

ACGACAGAAGGAGAGCAGAAG

ATGTCCACCAGGGTCTCAATC

GGGATGTTCAGGTCCATCAG

CACACTGTAGTTGTGCAGTCAA

CCTCGTTCACCCAGAAGGTC

GATTCCGGCGTCTACGTGTG

Mouse

ChIP
Primers
INHA
HRE 1
INHA
HRE 2
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Figure 2.1. INHA is increased in response to hypoxia in ovarian cancer cells. A)
Relative qRT-PCR analysis of (i) INHA and (ii) VEGFA mRNA expression normalized to
levels in 20% O2 in HEY and OV90 cells exposed to indicated oxygen concentration for
24hrs. MeanSEM, (n=3). *, p<.05; **, p<.01; ***, p<.001; ****, p<.0001, One-way
ANOVA followed by Tukey’s multiple comparison. (iii) Western blot of HIF-1
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stabilization at indicated oxygen concentrations. B) Relative qRT-PCR analysis of (i)
INHA and (ii) VEGFA mRNA expression normalized to corresponding levels in normoxia
in indicated cells grown under hypoxia (0.2%) or normoxia (17-21%) for 24hrs except for
OVCAR5 (12hrs). MeanSEM, n of independent trials for PA1=3, OVCAR5 n=7, HEY
n=3, OV90 n=3, *, p<.05; **, p<.01, unpaired t-test. (iii) Western blot of HIF-1
stabilization in indicated cell lines. C) Relative qRT-PCR analysis of INHA mRNA
expression normalized to corresponding levels in normoxia in HMEC-1 cells grown under
hypoxia (0.2%) or normoxia (17-21%) for either 12 or 24hrs. MeanSEM, n=3 for 12hrs
and 2 for 24hrs. n.s., not significant, unpaired t-test. D) (i) Western blot of HIF-1 levels
in HEY and OV90 following exposure to hypoxia (0.2% O2) for 24hrs and after indicated
re-oxygenation times. (ii) Relative qRT-PCR analysis of INHA expression in HEY and
OV90 cells following exposure to hypoxia (0.2% O 2) and indicated re-oxygenation time
normalized to corresponding levels in normoxia. MeanSEM, (n=3). *, p<.05; **, p<.01,
One-way ANOVA followed by Tukey’s multiple comparison.

61

Figure 2.2. Inhibin protein is secreted by ovarian cancer in response to hypoxia. A)
Total inhibin ELISA (inhibin A/B, inhibin) of conditioned media collected from OV90
and HEY cells grown in normoxia or after 24hr exposure to hypoxia (0.2% O 2).
MeanSEM, (n=3). **, p<.01, unpaired t-test. B) Relative qRT-PCR analysis of INHBA
and INHBB mRNA expression normalized to corresponding levels in normoxia in OV90
or HEY cells grown under hypoxia (0.2%) or normoxia (17-21%) for 24hrs. MeanSEM,
n=3. N.s., not significant, unpaired t-test.
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Figure 2.3. Inhibin is increased in ovarian cancer spheroids, patient samples, and
tumor xenografts. A) (i) Western blotting of HIF-1 protein from indicated cells grown
in either 2D or under anchorage independence (3D) conditions, vinculin is loading control
and (ii) relative qRT-PCR of INHA mRNA expression in OVCA420 and PA1 after 48hrs
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(OVCA420) or 72hrs (PA1) of growth under anchorage independence (3D). MeanSEM,
n=3. **, p<.01; ***, p<.001, unpaired t-test. B) Total inhibin ELISA of ascites fluid from
25 ovarian cancer patients sorted by stage. C) (i) Representative images of pimonidazole
staining in HEY xenograft tumors used for calculation of hypoxic area. Scale bar: 500m.
(ii) Percent hypoxic area in tumors of indicated size range determined by quantitation of
pimonidazole staining in tumors (i). Graph represents average hypoxic area of all HEY
xenograft tumors sorted by size as <500mm3 or >500mm3. MeanSEM, n=4 for <500mm3
and n=7 for >500mm3. *, p<.05, unpaired t-test. D) (i) Relative qRT-PCR of INHA
expression in tumors from indicated sizes of HEY cells implanted subcutaneously.
MeanSEM, n=8. ***, p<.001, unpaired t-test. (ii) Correlation analysis of INHA
expression and HEY subcutaneous tumor volume (mm3). (E) Correlation analysis between
INHA expression and either (i) Buffa or (ii) Winter hypoxia scores from TCGA OVCA (iii) or breast (iii) cancer patient data sets from cBioportal measured by RNA-Seq.
Correlation analysis was performed by Pearson correlation.
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Figure 2.4. HIF-1 is required for INHA expression under hypoxia. A) (i) Western blot
of HIF-1 at indicated time points after treatment with 100M CoCl2. (ii) Relative qRTPCR analysis of INHA and VEGF mRNA in OVCAR5 and PA1 cells after indicated time
of treatment with 100M of CoCl2 normalized to untreated. MeanSEM, (n=2). *, p<.05;
**, p<.01, One-way ANOVA followed by Tukey’s multiple comparison. B) Relative qRTPCR analysis of INHA and ARNT mRNA in HEY shControl or shARNT cell lines after
exposure to hypoxia (0.2% O2) for 24hrs normalized to corresponding shControl normoxia
levels. MeanSEM, (n=4). n.s.,not significant; *, p<.05; **, p<.01, unpaired t-test. C)
Representative western blot (above) and relative qRT-PCR analysis of INHA expression
(below) from (i) HEY or (ii) OV90 cells transfected with either siScr, siHIF-1, siHIF2, or a combination of siHIF-1/2 and exposed to hypoxia (0.2% O2) for 24hrs.
MeanSEM, (n=3) *, p<.05; ***, p<.001; ****, p<.0001, One-way ANOVA followed by
Tukeys multiple comparison test.

65

66

Figure 2.5. INHA is a direct target of HIF-1 A) Schematic of INHA promoter containing
location of hypoxia response elements (HRE), hypoxia ancillary sequences (HAS), cAMP
response element (CREB), and ChIP primers. Schematic is drawn to scale with appropriate
scale information below. B) Relative qRT-PCR analysis using primers that amplify the (i)
proximal HRE region in the INHA promoter or (ii) distal HRE region after chromatin
immunoprecipitation (ChIP) of HIF-1 in OVCAR5 and OV90 cells. ChIP qRT-PCR
results were quantified as normalized enrichment over IgG and normalized to normoxia.
MeanSEM, OVCAR5 (n=3), OV90 (n=2). n.s.,not significant; *, p<.05; **, p<.01, Twoway ANOVA followed by Fishers LSD test. C) Luciferase activity of HEK293 cells
transfected with the INHA promoter driven luciferase reporter construct (pGL4.10) and a
SV-40 renilla control vector. Cells were either (i) exposed to hypoxia (0.2% O2) or (ii) cotransfected with HIF-1 overexpression plasmid (HIF-1 ODD) and luciferase activity
measured and normalized to either normoxia in (i) or PCDNA3.1 in (ii). MeanSEM, n=3
(Hypoxia), n=2 (HIF-1ODD) *, p<.05; **, p<.01, unpaired t-test. D) (i) Representative
western blot and (ii) relative qRT-PCR analysis of INHA expression from HEK293 cells
transfected with either siScr, siHIF-1 or siHIF-2 and exposed to hypoxia (0.2% O2) for
24hrs. MeanSEM, (n=4). *, p<.05; ***, p<.001; ****, p<.0001, One-way ANOVA
followed by Tukeys multiple comparison test E) (i) Relative qRT-PCR analysis of INHA
mRNA from ID8ip2 cells treated with either 10M H89 or 20M forskolin (Fsk), grown
under normoxia or hypoxia 0.2% O2 for 24hrs and normalized to normoxia. MeanSEM,
n=3. (ii) Relative qRT-PCR of INHA mRNA from OV90 cells treated with 10M H89 and
grown under normoxia or hypoxia (0.2% O2) for 24hrs and normalized to normoxia.
MeanSEM, n=3.
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Figure 2.6. Inhibin increases hypoxia induced angiogenesis and endothelial cell
migration and permeability in vivo and in vitro respectively. A) (i) Hemoglobin content
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in Matrigel plugs collected 12 days after subcutaneous injection of HEY conditioned media
collected from cells exposed to normoxia or hypoxia for 24hrs and mixed with either 2g
of IgG or of anti-inhibin R1 antibody. MeanSEM, n=6 plugs per condition. n.s., not
significant; ***, p<.001, One-way ANOVA followed by Tukey’s multiple comparison test.
(ii) Representative images of Matrigel plugs from (i) Scale bar: 2mm. B) Quantitation of
HMEC-1 migration through fibronectin coated 8m trans-well filter (i-ii) towards
conditioned media from OV90 or HEY cells exposed to hypoxia (0.2% O 2) with either 2g
of R1 or PO23 anti-inhibin antibody or IgG as a control, or towards (iii) serum free media
containing 1nM inhibin A or 1nM VEGF A. Nuclei from three representative fields per
filter were counted. MeanSD. **, p<.01; ***p<.001; ****, p<.0001, One-way ANOVA
followed by Tukey’s multiple comparison. C-D) Quantitation of endothelial cell
permeability by measuring FITC-dextran changes across a HMEC-1 monolayer treated
with (i-ii) conditioned media from (i) OV90 or (ii) HEY cells exposed to hypoxia (0.2%
O2) with either 2g of R1 or PO23 anti-inhibin antibody or IgG as a control, or (D) treated
with 1nM inhibin A or 10g/mL LPS. MeanSEM *, p<.05; ***p<.001; ****, p<.0001,
One-way ANOVA followed by Tukey’s multiple comparison. E) HEY trans-endothelial
migration (TEM) across HMEC-1 monolayer either treated with inhibin A for 4 hrs or
untreated. (i) Representative transmigrated GFP positive HEY cells and (ii) quantitation of
transmigration (n=3). *, p<.05, unpaired t-test. Scale bar: 100m.

69

Figure 2.7. Inhibin increases endothelial cell contractility. A) (i) Representative
immunofluorescence images of F-actin (red) or VE-Cadherin (green) from HMEC-1 cells
grown to confluence on fibronectin coated coverslips and treated with either 1nM inhibin
A or 1nM VEGF A for 30 minutes. (ii) Quantitation of actin stress fibers from (i) using
ImageJ Fibril tool plugin (Methods). ***p<.001; ****, p<.0001, unpaired t-test. Scalebar:
25m. B) HMEC-1 grown to confluence were treated with 1nM Inhibin A for indicated
time. Lysates were immunoblotted for VE-cadherin and -Actin .C) (i) Western blot
analysis of pMLC-2 from HMEC-1 cells upon 1nM inhibin A treatment for indicated times.
(ii) Quantitation of pMLC-2 changes in (i).
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Figure 2.8. Inhibin promotes VE-cadherin internalization in endothelial cells. A)
Schematic of VE-cadherin internalization (Methods). B) (i) Representative
immunofluorescent images of (upper panel) cell surface labeled VE-cadherin at 4C
detected by labeling with an extracellular domain anti-VE-cadherin antibody. (Lower
panel) efficiency of stripping of extracellular labeled VE-cadherin with a mild acid. (ii)
Internalized VE-Cadherin at 37C detected with a FITC-secondary antibody in either
untreated or cells treated with 1nM inhibin A or 1nM VEGF A after acid wash. Green
arrows represent internalized VE-cadherin. Red, actin. Blue, DAPI. Quantitation of
internalized VE-Cadherin at (iii) T0 or (iv) T30 by Blobfinder ImageJ Plugin (Methods). *,
p<.05, unpaired t-test. Scalebar: 25m.
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Figure 2.9. Inhibin promotes endothelial cell permeability via ALK1 and endoglin. A)
Quantitation of endothelial cell permeability by measuring FITC-dextran changes across a
HMEC-1 monolayer treated with 1nM inhibin A in the presence or absence of (i)
100g/mL TRC-105 or (ii) 10 ng/mL ALK1-Fc. FITC-dextran diffusion across the HMEC1 monolayer is presented. MeanSD, n=4 for i and n=3 for ii. n.s., not significant; ***,
p<.001; ****, p<.0001. B) Relative qRT-PCR analysis of ENG mRNA expression in
MEEC WT or MEEC ENG-/-. C) Schematic of internalization of VE-cadherin measured
by cell surface biotinylation. Biotin labeling of cell surface proteins was performed on
MEEC WT or MEEC ENG-/-. Internalization was induced by treatment with 1nm Inhibin
A for 30 minutes at 37C followed by stripping of cell surface biotin. Internalized VE72

cadherin was detected by IP with neutravidin resin and D) (i) immunoblotting with antiVE-cadherin and (ii) quantitated as internalized VE-cadherin over input VE-cadherin
normalized to 37C control. MeanSD, n=2. n.s., not significant; *, p<.05, unpaired t-test.
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Figure 2.10. Inhibin increases ALK1-endoglin cell surface complexes while reducing
ALK4-endoglin complexes. A-B) Patch/FRAP studies on the effect of Inhibin A on
endoglin-ALK1 (A) and endoglin-ALK4 (B) complex formation. COS7 cells were
transfected with myc-ALK1 and HA-endoglin (A) or with (each vector myc-ALK4 and
HA- endoglin (B) (each vector alone, or together). C) After 24 h, singly transfected cells
were labeled for FRAP by anti-tag Fab’ followed by fluorescent secondary Fab’ (Methods)
and subjected to FRAP studies. For patch/FRAP, cells were subjected to protocol 1 of IgGmediated patching/cross-linking (CL) (Methods), resulting in HA-endoglin patched and
labeled by Alexa 488-GR IgG (designated “CL: IgG HA”), whereas myc-ALK1 is
labeled by monovalent Fab' (with secondary Alexa 546-GαM Fab’). In control experiments
without HA-endoglin CL, the IgG labeling of the HA tag was replaced by exclusive Fab'
labeling. Where indicated, inhibin A (4 nM) was added during the fluorescent labeling step
and maintained throughout the measurement. Representative FRAP curves are depicted in
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panels (i-iii), showing the lateral diffusion of singly-expressed myc-ALK1 (i), singly
expressed HA-endoglin immobilized by IgG CL (ii) and of myc-ALK1 in the presence of
co-expressed and IgG-crosslinked HA-endoglin in the presence of inhibin A (iii). Panels
(iv-v) depict average Rf (iv) and D values (v) of multiple experiments. Bars represent Mean
± SEM values, with the number of measurements (each conducted on a different cell)
shown in each bar. Some of these numbers are lower in the D values panels, since only Rf
can be extracted from FRAP curves yielding less than 20% recovery. Asterisks indicate
significant differences between the Rf values of the pairs indicated by brackets (****, p <
1 × 10-15; ***, p = 1 × 10-9; one-way ANOVA followed by Bonferroni post-hoc test). B)
Cells were labeled for patch/FRAP using protocol 2 (Methods), leading to immobilization
(CL) of the myc-endoglin and Fab’ labeling of HA-ALK4, whose lateral diffusion was then
measured by FRAP. (i) Average Rf values. (ii) Average D values. Bars are mean ± SEM
with number of measurements (n) depicted in each bar. Asterisks indicate significant
differences between the Rf values of the pairs indicated by brackets (****, p < 1 × 10-15;
**, p = 5.6 × 10-3; one-way ANOVA followed by Bonferroni post-hoc test). No significant
differences were found between D values following myc-endoglin immobilization.
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Figure 2.11. Targeting inhibin decreases in vivo subcutaneous growth. A) Growth
curves of subcutaneously implanted HEY shControl or shINHA tumors exposed to either
normoxia or hypoxia (0.2% O2) 24hrs prior to injection. 10mg/kg R1 antibody or vehicle
control was intraperitoneally injected three times a week. MeanSEM, n=10 for vehicle
and n=6 for R1 receiving groups. **, p<.01; ****, p<.0001, Two-way ANOVA followed
by Tukey’s multiple comparison test. B) Relative qRT-PCR analysis of INHA mRNA
expression in HEY shControl and shINHA cells (i) prior to subcutaneous injection and (ii)
at end point after harvest normalized to shControl. MeanSEM, n=2. C) Weight of Ncr
nude mice across two-week time course of anti-inhibin R1) or IgG antibody delivery.
Injections were given every other day starting at 5mg/kg and escalated to 10mg/kg after 7
days.
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Figure 2.12. Targeting inhibin alters vasculature in subcutaneous xenografts. A)
Growth curves of HEY shControl or shINHA after indicated time under hypoxia (0.2% O2).
Data is normalized to growth under normoxia after 72hrs. MeanSEM, n=2. n.s., not
significant, unpaired t-test. B) Fold change of proteins most altered in shControl and
shINHA tumors (Fig 7A) using the (i) human or (ii) mouse angiogenesis proteome array.
(n=2 tumors per group).C) (i) Average tumor volume of HEY shControl or shINHA
subcutaneous tumors used for analysis of vasculature and permeability in ii and iii.
MeanSEM, n=4. (ii) Quantitation of extravasated rhodamine-dextran (red) shown as
signal per 10x field from tumors in Fig 7Ci (Methods). MeanSD. n=12 fields from 4
tumors. ***, p<.001, unpaired t-test. (iii) Representative images of rhodamine-dextran
(red) extravasation into either shControl or shINHA subcutaneous tumors from C.i
Scalebar:100m D) (i-ii) Quantitation of average (i) vessel number and (ii) size in a 10x
field using ImageJ (Methods). MeanSD. n=8 which represents averages of 8 fields in 4
tumors from C.i. (iii) Representative images of CD-31 (red) stained blood vessels in HEY
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shControl and shINHA subcutaneous tumors from Fig 7Ci. Scalebar:100m, insets
scalebar: 20m. *, p<.05; **, p<.01, unpaired t-test.
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Figure 2.13. Inhibin is correlated with CA125 in patient ascites. A) Correlation analysis
of total inhibin (pg/mL) and CA125 (pg/mL) in patient ascites. B) Median age of patients
used for patient ascites ELISA analysis.
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CHAPTER 3
A BIOINFORMATIC ANALYSIS OF THE INHIBIN-BETAGLYCANENDOGLIN/CD105 NETWORK REVEALS PROGNOSTIC VALUE IN
MULTIPLE SOLID TUMORS2

Listik, E.; Horst, B. et al. A bioinformatic analysis of the inhibin-betaglycanendoglin/CD105 network reveals prognostic value in multiple solid tumors. PLoS One
16, e0249558, doi:10.1371/journal.pone.0249558 (2021).
2
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3.1 Introduction
Inhibins and activins are dimeric polypeptide members of the TGF-β superfamily,
discovered initially as regulators of follicle-stimulating hormone (FSH) 1,5,181-187. Activins
are homodimers utilizing different isoforms of the monomeric βA or βB subunits located on
different chromosomes

3,188,189

. Inhibin is a heterodimer of an α subunit (INHA) and a β

subunit (either βA, INHBA, or βB, INHBB). Thus, the inhibin naming reflects the β subunit
in the heterodimer: inhibin A (α/βA) and inhibin B (α/βB), respectively 2,4,5,190,191.
Activins, signal primarily through the transcriptional proteins SMAD2/3, much like
TGF-β

43,192.

Initial receptor binding of activin occurs via type II serine-threonine kinase

receptors (ActRII or ActRIIB). These then recruit and phosphorylate type I serinethreonine kinase receptors (ActRIB/Alk4 or ActRIC/Alk7) leading to subsequent
phosphorylation of SMAD2/35,43,45,193-195. In multiple tissues, activin signaling is
antagonized by inhibin

49.

Thus, the biological and pathological function of activin is

directly impacted by the relative levels of the mature α subunit. Inhibins, however, have a
much lower affinity for the type II receptors compared to activins themselves. The affinity
can be greatly enhanced by the presence of the Type III TGFβ receptor, betaglycan
(TGFBR3), which binds inhibin’s α subunit with high affinity

5,45,49,54.

Thus, the most

established mechanism of antagonism by inhibin, is via its ability to competitively recruit
ActRII preventing activin induced downstream signaling in a betaglycan-dependent
manner

5,45,49,54.

This competition model does not allow for direct inhibin signaling.

However, conflicting reports on the presence of a separate high affinity inhibin receptor
48,196,

recently discovered interactions of the α subunit with the Type I receptor Alk4

54,

and our recent findings on the requirement of the alternate Type III TGF-β co-receptor
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endoglin (ENG/CD105) for inhibin responsiveness in endothelial cell function

57

suggest

complex roles for inhibins themselves.
Betaglycan and endoglin, are both coreceptors of the TGF-β superfamily with broad
structural similarities 197-199, including glycosylation in the extracellular domain (ECD), a
short cytoplasmic domain and common intracellular interacting partners

200-205.

Sequence

analysis of betaglycan and endoglin reveal the highest shared homology in the
transmembrane (73%) and cytoplasmic domains (61%), with the most substantial
difference being in the ECD sequence that impacts ligand binding

197-199,206-208

. Both

betaglycan and endoglin knockouts (KOs) are lethal during embryonic development due to
heart and liver defects and defective vascular development, respectively, highlighting the
shared physiological importance of these coreceptors

209-212.

In contrast to the above-

described similarities, betaglycan is more widely expressed in epithelial cells, while
endoglin is predominantly expressed in proliferating endothelial cells 58,213,214.
In cancer, betaglycan and endoglin impact disease progression by regulating cell
migration, invasion, proliferation, differentiation, and angiogenesis in multiple cancer
models

203,215-220.

Betaglycan can act as a tumor suppressor in many cancer types and its

expression is lost in several primary cancers 221-223. However, elevated levels of betaglycan
have also been reported in colon, triple-negative breast cancers and lymphomas, with a role
in promoting bone metastasis in prostate cancer
betaglycan in tumor progression

216,225,226.

224,

indicating contextual roles for

Endoglin is crucial to angiogenesis, and

increased endoglin and tumor micro-vessel density is correlated with decreased survival in
multiple cancers

218,227.

Evidence in ovarian cancer

176,228

also suggests that endoglin

expression may impact metastasis. Inhibins have been robustly implicated in cancer, and
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much like other TGF-β members may have dichotomous, context-dependent effects
75,84,229-231.

19,73-

Inhibins are early tumor suppressors, as the INHA-/- mice form spontaneous

gonadal and granulosa cell tumors

19.

However, elevated levels of inhibins in multiple

cancers are widely reported 66,73-75,128,229. Active roles for inhibins in promoting late stage
tumorigenesis, in part via effects on angiogenesis, have also been reported in both prostate
cancer 77 and more recently in ovarian cancer 57.
Inhibins have been widely used as a diagnostic marker for a subset of cancers
66,128,232

and both betaglycan and endoglin have been evaluated as therapeutic strategies in

cancer. TRC-105, a monoclonal antibody against endoglin, was tested in twenty-four
clinical trials

233-256.

Current data also suggest benefits of combining anti-endoglin along

with checkpoint inhibitors

257.

Similarly, a peptide domain of betaglycan called p144 and

soluble betaglycan have been tested in multiple cancer types as an anti-TGF-β treatment
strategy that decreases tumor growth, angiogenesis, metastasis, and augments
immunotherapy 258-265.
Prior and emerging studies reveal the dichotomous functions of inhibin’s on cancer
depending on either betaglycan

5,45,49,54

or endoglin

57.

Hence, further characterization of

the relationship between inhibins-betaglycan-endoglin is vital. This study seeks to provide
such prescient information by evaluating the significance, impact, and predictive value of
this specific network (INHA, INHBA, INHBB, TGFBR3, and ENG) by utilizing publicly
available genomic and transcriptomic databases.
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3.2 Materials and Methods
Public databases data mining
Clinical data, gene expression alterations, and normalized expression data of RNA-seq
were obtained from cBioPortal 141,148. All available studies were assessed for copy number
alterations (CNA) and a subset of cancer for mRNA data (Breast Invasive Carcinoma,
Glioblastoma, Lower-grade glioma, Cervical Squamous Cell Carcinoma, Stomach
Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Kidney Renal Clear Cell and
Renal

Papillary

Cell

Carcinomas,

Liver

Hepatocellular

Carcinoma,

Lung

Adenocarcinoma, Ovarian Serous Cystadenocarcinoma, Prostate Adenocarcinoma,
Uterine Corpus Endometrial Carcinoma). The results shown here are partly based upon
data generated by the TCGA Research Network: https://www.cancer.gov/tcga. Survival
data was generated from either KM Plotter266 or cBioportal (i.e., brain cancers). KM Plotter
data for breast, ovarian, lung, and gastric cancer the survival analysis was derived using
available gene chip data sets. All others were derived using the RNA-Seq Pan-cancer data
sets. The Affymetrix Probe IDs used in gene chip analysis in KM Plotter were: INHA
(210141_s_at), INHBA (204926_at), INHBB (205258_at), TGFBR3 (204731_at), and ENG
(201808_s_at). Brain cancer data was generated from TCGA Pan Cancer Atlas 2018
dataset for glioblastoma and low-grade glioma. Overall survival (OS) was assessed for all
cancer types except ovarian cancer (progression-free survival, PFS) and breast cancer
(relapse-free survival, RFS). Gene expression was split into high and low using the median
expression. Log-rank statistics were used to calculate the p-value and Hazard ratio (HR).
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Analysis of gene predictiveness to pharmacological treatment
Gene predictive information on treatment regiments was obtained from ROC
Plotter (http://www.rocplot.org/)

267.

Gene expression for the analyzed genes was

compared using the Mann-Whitney U test. Receiver Operating Characteristic (ROC) plots
and significance was also computed. ROC curves were compared using Area Under the
Curve (AUC) values, and values above 0.6 with a significant p value were considered
acceptable

267.

ROC plot assessment was performed in all pre-established categories in

ROC Plotter (i.e., breast and ovarian cancers, and glioblastoma). In breast cancer, subtypes
(i.e., luminal A, luminal B, triple-negative, HER2+) were also analyzed separately. Genes
of interest were analyzed for complete pathological response in different pharmacological
treatments. All available treatment options were investigated including, taxane,
anthracycline, platin and temozolomide. Outliers were set to be removed in this analysis
and only genes with a false discovery rate (FDR) below 5% were considered.
Clustering strategies for genes signatures
From the normalized expression data from RNA-seq studies, the Spearman’s ρ
coefficient was obtained for INHA, TGFBR3, and ENG. These data were clustered through
a Euclidean clustering algorithm using Perseus 1.6.5.0 (MaxQuant). Clusters containing
high and low correlations sets were isolated and compared in a pair-wise fashion. The
derived genes obtained were checked for protein interaction in BioGRID (thebiogrid.org)
268,

and later included in pathway analysis, as described in section 2.5. All plots were

performed in GraphPad Prism 8.0.
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Gene signature modeling for prognostics
Gene signature modeling was performed using binary probit regression for each set
of cancer types related to INHA, TGFBR3, ENG (S5 Table), and their respective outcomes
(i.e., positive, 1; or negative, 0). The regression was iterated for presenting only significant
elements in the following model:
𝑘

Pr(𝑌 = 1|𝑥1 , … , 𝑥𝑘 ) = Φ (𝛽0 + ∑ 𝛽𝑖 𝑥𝑖 )
𝑖=1

in which 𝑥𝑖 are RNA-seq V2 RSEM expression data for each gene, 𝛽𝑖 are obtained
coefficients from this regression, Φ is the cumulative normal distribution function.
Probability values closer to 1 indicate a positive outcome, while values close to 0, indicate
a negative outcome. Postestimation of specificity and sensitivity was also implemented.
All regression studies were performed in Stata/SE 16.0.
Pathway assessment
For pathway analysis, DAVID Bioinformatics Resources 6.8 was used to acquire
compiled data from the KEGG Pathway Database

269.

Genes for the analysis were

annotated to map to human pathways. The significant outputs were then assessed for the
percentage of genes from analyzed sets and their relevance. To compare pathways between
two sets, a pathway significance value ratio (-log10R), in which R is the ratio, was analyzed.
Only pathways with an FDR value below 5% were considered.
Gene dependency analysis
Gene dependency of INHA, TGFBR3, INHBA, INHBB, and ENG was analyzed
using the DepMap portal (www.depmap.org)

270.

Gene expression from Expression

Public20Q1 (accessed between March and April 2020) were compared to the cell line
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database from CRISPR (Avana) Public20Q1 and Combined RNAi (Broad, Novartis,
Marcotte). Gene effect values of less than or equal to -0.5 were used to select dependent
genes. To analyze gene co-dependency, Expression Public20Q1 was compared to all
CRISPR and RNAi databases. A gene was considered dependent when correlations
between datasets displayed similar trends. Each dependent gene-set was compared between
INHA, TGFBR3, INHBA, INHBB, and ENG to count duplicates. The number of dependent
genes were plotted as a Venn diagram.

3.3 Inhibins and activins are altered in human cancer
We and others reported previously diverse roles for members of the inhibin/activin
family in cancer

5,57,271-274.

Our and prior mechanistic studies in cancer indicate a strong

dependency of inhibin function on betaglycan and endoglin

50,53,54,57,275,276.

To begin to

evaluate the impact of this relationship more broadly in cancers we analyzed gene
alterations including mutations, amplifications, and deletions for the genes encoding
inhibin/activin subunits (Figure 3.1A) INHA, INHBA, INHBB, and the key coreceptors —
TGFBR3, and ENG in all public datasets available in cBioPortal (Figure 3.1B). While
INHBC and INHBE are activin subunits, these were excluded from the analysis as they
have not been demonstrated to form heterodimers with INHA277.
Percentage of patients from the whole cohort that possessed any of the alterations
either by themselves or concomitantly was analyzed. We find that melanoma (16.26%),
endometrial (13.16%), esophagogastric (10.85%), and lung (10.69%) cancers revealed the
highest alterations for the genes. The alterations for the genes varied, with INHBA and
TGFBR3 exhibiting higher rates of alterations (0–5.65% and 0.17–3.91% respectively) that
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also varied by cancer type. The range for INHA, INHBB, and ENG was found to be between
0–2.38%, 0–2.62%, and 0–3.23% respectively (Figure 3.1B).
In comparing expression levels of each of the genes in the same TCGA datasets as
in Figure 3.1B, we find that overall, ENG is the most highly expressed gene (Figure 3.1C)
with variance among different cancer types (e.g., lower-grade glioma and cervical vs. renal
clear cell and lung adenocarcinoma, p < 0.0001) and subtypes (e.g., luminal A vs. luminal
B breast cancers, p < 0.0001). Interestingly, TGFBR3 expression differed most notably
between glioblastoma and lower-grade gliomas (p < 0.0001). Breast cancers exhibited
higher expression as compared to ovarian and endometrial (p < 0.0001) cancers. INHBB in
contrast was mostly expressed in renal clear cell and hepatocellular carcinomas, which
differs from renal papillary cell carcinoma and cervical cancer (p < 0.0001). Both INHBA
and INHA were the least expressed as compared to the others (Figure 3.1C). Exceptions
were head and neck and esophagogastric cancers that had high expression of INHBA and
lung adenocarcinoma and renal clear cell carcinoma that had high expression of INHA.
While the above analysis examined patient tumors, we next examined cell lines as
a way to delineate model systems for future studies. For these analyses, we used the
DepMap project (www.depmap.org) 270 which is a comprehensive library of human genes
that have been either knocked down or knocked out through CRISPR technology in 1,776
human cell lines representing multiple cancer types 278-280. Dependency scores representing
the probability of queried gene dependency for each cell line and thereby cancer type is
obtained

281.

Here, we find that the ligand encoding gene INHA displayed higher

dependency than the activin subunit isoforms INHBA or INHBB or either receptors
TGFBR3 or ENG (Figure 3.1D). Notably, esophageal, gastric, and ovarian cancers had the
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highest dependency results for INHA (≥ 14%) consistent with the alterations seen in Figure
3.1C. Within these cancers, INHBA exhibited higher dependency values in ovarian cancer
(6%) albeit not as high as INHA. Besides INHBB in myeloma (6%), no other notable
dependency relationships were observed.
In an attempt to identify genes most impacted by alteration to each of the individual
genes, we examined how RNAi and CRISPR interventions would affect their correlation
to specific genes. Those similarly affected by these techniques were found to be dependent
on the investigated set of genes. We find that ENG exhibited the highest number of
dependent genes (Figure 3.1E, n = 71). Interestingly, only a total of 5 genes were
commonly dependent between INHA and the other genes (Figure 3.1E, MAX with INHBA
and GRPEL1, SF3B4, ESR1, and TFAP2C with INHBB). INHBA on the other hand had
several common dependent genes most notably 13 genes were common with ENG
dependency (e.g., VCL, TLN1, and LYPD3).

3.4 Effect of inhibins and the coreceptors on patient survival varies by
cancer type
Since alterations in expression of inhibin, activin, TGFBR3 and ENG exist in
human cancers and prior studies have implicated each of these in patient outcomes
57,128,220,227,271,282-285;

we conducted a comprehensive analysis of each of these genes on

overall survival (OS), progression-free survival (PFS), or relapse free survival (RFS) in a
broad panel of cancers. The goal here was to identify the patients and cancer types most
impacted by changes in gene expression. Analysis was conducted using datasets in KM
Plotter (summarized in Table 3.1)

266

. For ovarian cancer data sets, only p53 mutated

ovarian cancers were included. Patients in KM plotter with p53 mutation status known
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showed 83% were mutated, cBioportal data sets showed 82.5% frequency of p53 mutation,
and it has been reported that over 90% of ovarian cancers present p53 mutations. We find
that not all cancers are equally impacted. Of note, we find that in both breast and ovarian
cancers all five genes were either positive predictors of survival or non-predictive except
INHBB in breast (HR = 1.06, p = 0.034) and INHBA in ovarian (HR = 1.16, p = 0.047)
(Figure 3.2). However, in p53 mutated cancers, INHA was a strong negative predictor of
survival for both breast and ovarian cancers (HR=1.99, p = 0.0056 and HR = 1.55, p =
0.0039, respectively), along with ENG in ovarian cancer (HR = 1.36, p = 0.0098, Figure
3.2). Additionally, in lung cancers, INHA and ENG differed from TGFBR3, as INHA
(HR=1.26, p = 0.00029) and ENG (HR = 1.20, p = 0.0056) were both negative predictors
of survival while TGFBR3 (HR = 0.65, p = 3.4E-7) was a strong positive predictor of
survival (Figure 3.2). Specifically, we find that INHA and ENG are robust predictors of
poor survival in lung adenocarcinomas but not in squamous cell carcinomas (Figure 3.2).
Gastric cancers represent another robust cancer type where all five genes were negatively
correlated with survival (Figure 3.2). Since HER2 expression is a frequent abnormality in
gastric cancer

286,

we examined if there were any differences in survival associated with

HER2 expression. All five genes in both HER2+ and HER2- gastric cancers, except INHBA
in HER2- gastric cancers, were negatively correlated with survival (Figure 3.2). In kidney
cancers, INHA was a negative predictor of survival in both renal clear cell and renal
papillary cell carcinoma (Figure 3.2), consistent with prior findings

57.

TGFBR3 was a

strong positive predictor of survival in both renal clear cell carcinoma (HR = 0.46, p =
2.1E-7) and renal papillary cell carcinoma (HR = 0.53, p = 0.042, Figure 3.2). ENG (HR =
0.51, p = 8.6E-6) was a positive predictor of survival in renal clear cell carcinoma but not
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significantly associated with survival in renal papillary cell carcinoma (Figure 3.2). Finally,
in brain cancers, INHA was a negative predictor of survival in glioblastoma but a positive
predictor in low-grade gliomas (Figure 3.2). Of note, ENG appeared to have a lower range
of HR values compared to INHA and TGFBR3. INHBA and INBBB were not as
significantly correlated with survival as INHA, ENG, and TGFBR3. INHBA was
significantly correlated with 8 cancer types while INHBB was significantly correlated with
9. INHBA and INHBB showed similar correlations with survival in gastric cancers,
specifically HER2+, and renal papillary cell carcinoma (Figure 3.2). INHBA and INHBB
showed opposing effects however in liver cancer where INHBA (HR = 0.62, p = 0.0086)
was a strong positive predictor but INHBB (HR = 1.52, p = 0.025) was a potent negative
predictor (Figure 3.2).
Since inhibin’s biological functions have been shown to be dependent on the
coreceptors TGFBR3 and ENG 50,53,54,57,275,276, we examined the impact of INHA based on
the expression levels of each of the co-receptor (Table 3.2). In this analysis, we find that
that when separating patients into high or low expressing TGFBR3 or ENG groups (Table
3.2) in p53 mutated breast cancers, where INHA is a negative predictor of survival in all
patients (Figure 3.2), INHA was only a predictor of poor survival in patients with low
TGFBR3 (HR = 2.29, p = 0.015) or low ENG (HR = 2.24, p = 0.035). Interestingly, this
trend was also repeated in renal clear cell carcinoma, where INHA was only a predictor of
survival in TGFBR3 low (HR = 2.75, p = 9.0E-06) and ENG low (HR = 2.6, p = 2.5E-06,
Table 3.2). In contrast to breast and renal clear cell cancers where TGFBR3 and ENG both
impacted the effect of INHA on survival, TGFBR3 levels did not change INHA’s impact on
p53 mutated serous ovarian cancers (Table 3.2). In ENG high p53 mutated serous ovarian
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cancer patients, INHA had a more significant negative prediction outcome (HR = 2.12, p =
1.8E-6) compared to ENG low (HR = 0.8, p = 0.18, Table 3.2). Similar outcomes were
observed in lung adenocarcinomas with respect to TGFBR3, where INHA remained a
strong negative predictor of survival in patients regardless of TGFBR3 expression levels
(Table 3.2). However, INHA remained a robust negative predictor of survival in lung
adenocarcinomas patients expressing low ENG (HR = 2.12, p = 0.00041) but was not
significant in ENG high expressing patients (HR = 1.25, p = 0.14) (Table 3.2). Together,
these findings suggest that INHA expression as a predictive tool for survival is influenced
by the coreceptors ENG and TGFBR3 in renal clear cell, lung, and p53 mutated breast and
ovarian cancers. INHA is dependent on these coreceptors in all breast and ovarian cancers.

3.5 Inhibins and activins can predict response to chemotherapy in
luminal A breast cancer
We next evaluated the pathological response based classification for each of the
genes using the receiver operating characteristic (ROC) plotter (www.rocplot.org) to
validate and rank INHA, INHBA/B, TGFBR3 and ENG as predictive biomarker candidates
267.

In a ROC analysis, an area under the curve (AUC) value of 1 is a perfect biomarker

and an AUC of 0.5 corresponds to no correlation at all. We first entered all genes to allow
for FDR calculation for each gene at FDR cutoff of 5%We next examined individual genes
and find that in luminal A breast cancers ENG, TGFBR3, INHA, and INHBA, were better
performing as compared to INHBB particularly for taxane or anthracycline based
chemotherapy regimens. ROC plots for the two regimens are displayed in Figure 3.3A.
Both ENG and TGFBR3 were predictive in other cancer types as well (see
supplemental data for Chapter 3 citation). Specifically, while ENG performed better in
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taxane treatments in HER2+ breast cancer subtype, TGFBR3 performed better for taxane
regimens in triple-negative breast cancer (TNBC) and serous ovarian cancer. Interestingly,
examining expression (Figure 3.3B) revealed that in the same luminal A breast cancers
INHA, ENG and INHBA are less expressed in responders to pharmacological treatment
while TGFBR3 is more expressed in these responder groups (Figure 3.3B). Similar trends
for TGFBFR3 expression were seen in TNBC and serous ovarian cancer groups where
TGFBR3 was more expressed in the responders’ group for taxane regimens. ENG was also
more expressed in HER2+ breast cancer patients who respond to taxane therapy, which was
opposite to the luminal A subtype expression levels (Figure 3.3B). Full data for the ROC
curve assessment is available in supplemental data for Chapter 3 citation. In summary
INHA, INHBA, TGFBR3, and ENG display clear discrepant profiles of expression among
responders and non-responders to both anthracycline and taxane chemotherapy for distinct
breast cancer subtypes, specifically luminal A, and serous ovarian cancer. These genes also
harbor a possible predictive value to indicate responsiveness to these therapy regimens.
Moreover, ENG expression could also differentiate luminal A and HER2+ breast cancers
response to taxane therapy. INHBB on the other hand had no predictive value in the
assessed cancer types.

3.6 Gene signatures from inhibins can predict patient survival outcomes
INHA, TGFBR3, and ENG impact patient outcomes more broadly and more
significantly that INHBB and INHBA. There is also direct functional dependency of
TGFBR3 and ENG to inhibin rather than activin

207,287.

We thus examined signatures

associated with either a negative or positive outcome for each of the three genes. Cancer
types that presented different survival predictions for INHA, TGFBR3, or ENG were
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assessed (Figure 3.4A), and cancer types in which each gene would have a similar patient
outcome (i.e., positive overall survival outcome vs. negative overall survival outcome)
were separated into groups (e.g., INHA positive outcome vs. negative outcome, Figure
3.4A).
Spearman’s ρ coefficient was calculated for all RNA-seq gene data provided in
each of these datasets, and values were clustered, and genes that were either positively and
negatively correlated with each individual INHA, TGFBR3 or ENG genes were identified
(data located in citation). The top correlated genes from the positive outcome set were then
pairwise compared to genes that had lower correlations in the negative outcome set, and
vice-versa to obtain a subset of common genes

288-291.

Examples include TGFB2 and

HOXA1 where genes correlated to INHA in the negative outcome set, and OGG1 and
STAP2 in the positive outcome group. For TGFBR3, AP1M1 and RILPL1 correlated in the
negative outcome context, while FZD5 and MYCN in the positive one. No gene signatures
were obtained for ENG. As indicated in section 3.2, the HR value range was the smallest
for ENG in the assessed cancer types, which limits the differential gene signature analysis.
All these genes also had their mRNA expression assessed in the respective cancer sets,
contrasted, and evaluated for difference in expression (Figure 3.4B). Except for 22 genes
from sets in which INHA or TGFBR3 had distinct predictions of survival (e.g., CHSY1,
LDLR, PPARG, MIA2, TOX3) all others exhibited significant alterations in gene expression
(Figure 3.4B).
The altered genes from Figure 3.4B whose difference in expression was significant,
were assessed for protein interactions and these iterated for pathway analysis using
BioGRID (thebiogrid.org, Figure 3.4C) 268. We find that INHA gene sets were associated
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with either PD-L1 expression and PD-1 checkpoint, Rap1 signaling pathways in patients
with positive outcomes or cell cycle regulation in patients with negative outcomes.
TGFBR3 associated genes on the other hand, relied on VEGF and MAPK signaling
pathways for patients with positive outcome and IL-17, p53, or even Wnt signaling
pathways in the negative outcome scenario. Detailed descriptions of analyzed genes and
pathways are compiled in supplemental data for this manuscript (see Chapter 3 citation).
To determine if the genes associated with INHA and TGFBR3 had true prognostic
value, a Probit regression model was applied to the normalized mRNA expression of the
genes identified above. The regressions were analyzed for the cancers from Figure 3.2A
and Figure 3.2D which had clear outcomes for either INHA, or TGBFR3. The final
coefficients and entry genes are also provided in supplemental data for this manuscript (see
Chapter 3 citation). We find that the INHA model had 43 genes as dependent elements, and
the TGFBR3 model had 37 genes. However, the most suitable model obtained from these
sets is the TGFBR3 model, which has a high goodness of fit p-value (p = 0.9494),
sensitivity (98.42%), specificity (91.56%), and accuracy (96.70%, Table 3.3).
These analyses reveal that a differential signature obtained from INHA, along with
one of its main binding receptors (i.e., TGBFR3) are able to faithfully predict a patient’s
outcomes in a wide spectrum of cancer types (e.g., kidney, lung, head and neck, breast,
liver, ovarian, stomach, endometrial).

3.7 Functional analysis and interpretation of inhibin’s mechanism of
action
Prior functional studies indicate a dependency on ENG and TGFBR3 for inhibin
responsiveness

207,287.

To test if these biological observations hold in patient datasets, we
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performed supervised clustering using Euclidean algorithm of genes correlating with either
INHA, ENG or TGFBR3 using the RNA-seq data for cancer types with the most significant
impact as determined in Figure 3.5A. Only the most enriched transcripts that were either
positively or negatively correlated transcripts are shown in Figure 3.5A. Most enriched
genes from these clusters were then compared amongst each other in all pairwise
combinations for similarities (e.g., positively correlated to INHA vs. negatively correlated
to TGFBR3, and so on, Figure 3.5B).
We find that INHA and TGFBR3 comparison rendered 1,430 genes, in which 24.6%
were exclusive to INHA (e.g., DLL3, GPC2, TAZ, TERT, XYLT2) 37.7% to TGFBR3 (e.g.,
CCL2, CCR4, EGFR, GLCE, IL10RA, IL7R, ITGA1, ITGA2, JAK1, JAK2, SRGN, SULF1,
TGFBR2), and 13.1% were positively correlated to both (e.g., CSPG4, COL4A3, FGF18,
NOTCH4, SMAD9). When INHA was assessed with respect to ENG we find 1,773 genes
of which, 11.2% were exclusive to INHA (e.g., GDF9, PVT1), 21.3% to ENG (e.g., CCL2,
GPC6, IL10, IL10RA, IL7R, INHBA, ITGA1, ITGB2, JAK1, SRGN, SULF1, TGFB1,
TGFBR2) and 10.0% were highly correlated to both (e.g., CSPG4, DLL1, FGF18, FZD2,
NOTCH4). Lastly, the comparison between ENG and TGFBR3 returned 1,938 genes.
However, very few were exclusive to either TGFBR3 (2.84%) or ENG (0.16%), revealing
a high functional resemblance between both of these receptors, as most of the profiled
genes correlated to both of them (48.5%, e.g., ADAM9, -23, ADAMTS1, -2, -5, -8, -9, CCL2,
CSF1R, DLL4, ESR1, FGF1, FGF2, FGF18, GLI1, -2, -3, GPC6, IL10RA, ITGA1, ITGA5,
JAK1, MMP2, SDC3, SRGN, SULF1, TGFB3, TGFBR2, TNC, TWIST2, XYLT1, ZEB1) or
none of them.
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We next used each gene set from the cross-comparisons in Figure 3.5B to identify
pathways using KEGG 292. Unique pathways with an FDR below 5% were identified for
the comparisons and are presented in Figure 3.5C. Although several common pathways
were present between groups, such as PI3K-Akt and Ras signaling pathways (see
supplemental data in Chapter 3 manuscript citation), some unique pathways were present
as well. ENG, for instance, was more exclusively related to cytokine-cytokine receptor
interaction and natural killer mediated cytotoxicity (Figure 3.5C), while TGFBR3 was more
exclusively related to proteoglycans interaction and chemokine signaling. While cell cycle
and DNA replication were not directly associated with ENG and TGFBR3, Rap1 signaling,
and Extracellular matrix (ECM)-receptor interactions were both impacted by ENG and
TGFBR3 (Figure 3.5C). However, no independent pathway could be pinpointed to INHA
alone, revealing dependency on either TGFBR3 or ENG. These studies indicate that
inhibin’s effects may vary depending on whether ENG is more highly expressed as
compared to TGFBR3 with significant relevance to defining mechanism and impact of
changes in components of this pathway.

3.8 Discussion and Conclusions
This study aimed to evaluate comprehensively the influence of the inhibin-activin
network in cancer. Our findings provide significant new information on the specific cancers
impacted by the genes investigated here, INHA, INHBA, INHBB, ENG and TGFFBR3, and
shed light on potential functional dependencies. Additional gene signature analysis reveals
that INHA, along with one of its main receptors (i.e., TGBFR3) faithfully predicts patient
outcomes in a wide spectrum of cancer types.
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TGFβ-1 is a representative member of the TGF-β family that has been significantly
investigated previously 293. However, less information exists about the precise impact and
role of other members like inhibins and activins. Our findings that INHA is significantly
associated with survival in sixteen of the twenty cancers analyzed, correlating positively
with survival in five cancers and negatively in ten (Figure 3.2), highlight INHA’s
differential role as a tumor suppressor or promoter depending on the specific cancer type.
In highly angiogenic tumors like renal clear cell carcinoma

294

and glioblastoma

295,

we

found INHA expression to be a significant negative predictor of survival. INHA’s role in
promoting tumorigenesis in these cancer types may occur through its effects on
angiogenesis as has been previously reported for a subset of ovarian and prostate cancer
57,77

warranting further investigation. In Luminal A breast cancers, we observed that

increased INHA expression was associated with unresponsiveness to chemotherapy (Figure
3.3) while in survival data it was a positive predictor of survival (Figure 3.2). This apparent
contradiction can perhaps be explained by the fact that data in KM Plotter contains
information on patients that have undergone a wide array of treatments. Likely, INHA is
predictive of response to some treatments but not others. In both breast and ovarian cancers,
INHA was a negative predictor of survival in patients that had p53 mutations indicating a
potential dependency of INHA functions on the p53 status. INHA expression alterations
have been observed in p53 mutated adrenocortical tumors and INHA was suggested to be
a contributing factor to tumorigenesis in these cancers

296.

One of the most characterized

transcriptional activators of INHA is GATA4 297, which can also regulate p53 in cancer and
could contribute to the different survival outcomes observed for INHA in p53 mutated
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cancers versus wild-type p53 cancers

298,299.

INHA’s link to functional outcomes in the

background on p53 mutations remains to be fully elucidated.
Between the TGF-β family co-receptors (ENG and TGFBR3) implicated in cancer
progression and inhibin function, ENG was more expressed (Figure 3.1C), particularly in
lung adenocarcinoma and gastric cancers, corresponding with ENG being a strong negative
predictor of survival (Figure 3.1C and Figure 3.2). These findings are consistent with prior
experimental findings as well

300,301.

In p53 mutated cancers, ENG remained a negative

predictor. ROC Plotter analysis revealed decreased ENG expression to be associated with
response to anthracycline therapy in Luminal A breast cancer patients (Figure 3.3).
However, a previous study showed that positive ENG expression was associated with
increased survival in breast cancer patients who had undergone anthracycline treatment 302.
While Isacke and colleagues did not report a specific subtype in their analyzed cohort

302,

we obtained significant results for Luminal A breast cancer, specifically. Moreover, an
additional study performed in acute myeloid leukemia showed an inverse relationship to
that of Isacke et al., consistent with our results in Luminal A breast cancer 302,303. We also
found ENG to be a predictive of response to taxane therapy regimens. An inverse
relationship between ENG expression was observed in responders for Luminal A and
HER2+ breast cancer, with responders expressing high ENG in HER2+ breast cancers but
low levels of ENG in Luminal A cancers (Figure 3.3). As Luminal A breast cancer is HER2, ENG could be affected by HER2 status in these cancer types. In our analysis, expression
data was only obtained for Luminal A breast cancers not HER2+ so differences in
expression between the two were not analyzed.
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Consistent with TGFBR3’s role as a tumor suppressor in many cancers, we found
it to be a significant positive predictor of survival in all but two cancers (i.e., endometrial
and all gastric subtypes, Figure 3.2). Increased TGFBR3 was predictive of response in all
treatments and cancers we examined (Figure 3.3), further bolstering TGFBR3’s role as a
negative regulator of tumor progression. Specifically, Bhola et al. (2013)
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showed

increased levels of TGFBR3 in response to taxane in a small cohort (n = 17) of breast cancer
patients; however, response to therapy was not analyzed. TGFBR3 has been shown to act
as a tumor suppressor in renal clear cell carcinoma 282 and non-small cell lung cancers 261
which was also confirmed here (Figure 3.2). We were also able to expand TGFBR3’s role
in renal cancer to papillary carcinomas as well (Figure 3.2).
Expression of ENG and TGFBR3 was not significantly different between wild-type
and p53 mutated cancers indicating p53 likely does not impact expression itself. Whether
protein secretion of these coreceptors is altered in these cancers is currently unknown, and
cannot be ruled out, as previous studies have shown increased endoglin folding and
maturation in p53 mutation settings

305.

TGFBR3 also undergoes N-linked glycosylation,

so a similar scenario to endoglin is possible. Alterations in protein maturation could explain
the differential patient outcomes observed between wild-type and p53 mutated cancers,
when assessing for ENG and TGFBR3, despite changes in expression not being observed.
INHA’s dependency on each coreceptor examined in survival analysis revealed
distinct signatures between different cancer types (Table 3.2). Prior studies indicate a
requirement for ENG in inhibin responsiveness and functions 57, which was borne out in
patient survival data here (Table 3.2). However, a few outliers exist such as p53 mutated
breast and renal clear cell carcinoma where INHA was not always dependent on increased
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ENG and TGFBR3 expression. We found INHA to only be a negative predictor of survival
in patients expressing low ENG indicating INHA might act independent of coreceptor in
these cancer types. The role of other receptors involved in mediating INHA’s effects in
these cancer types remains to be determined.
Betaglycan and endoglin are co-receptors for TGFβ-1,2,3 and have been shown to
regulate signaling for isoforms of BMP, Wnt and FGF 306-308. However, both endoglin and
betaglycan are dispensable for response to the above-mentioned growth factors, playing
primarily modulatory functions. Given that TGF-β’s BMPs, Wnt, and FGF can act as both
tumor suppressors and promoters in a cancer and context dependent manner, and our
analysis indicating that ENG and TGFBR3 are both strong predictors of survival on their
own (Figure 3.2) it is likely that ENG and TGFBR3 expression levels impact signaling
sensitivity and thereby patient outcomes in the context of those signaling ligands.
In contrast to the above listed growth factors, Inhibins are reported to have
functional consequences that dependent primarily on betaglycan or endoglin 49,57 consistent
with the ability of the gene signatures (Figure 3.4) dependent on TGFBR3 and ENG to
distinguish patients’ outcomes. Some notable elements of this signature have been verified
previously and even proposed as cancer biomarkers. For example, EPHA2 overexpression
has been associated with decreased patient survival and promotes drug resistance,
increased invasion, and epithelial to mesenchymal transition (EMT)

309-312.

HOXA1, a

lncRNA overexpressed in cancers such as breast, melanoma, and oral carcinomas, drives
metastasis and tamoxifen resistance 313-315. For TGFBR3 specifically, three genes revealed
high discrimination between positive and negative outcomes: UGT1A9 and GLYATL1 were
25- and 35-fold more expressed in positive outcomes and P2RX3 was 11.5-fold more

101

expressed in negative outcomes. Of interest, UGT1A9 is a UDP-glucuronosyltransferase
(UGT) whose activity has been implicated in drug resistance by affecting the bioactivity
of the drug 316,317. We speculate that as a proteoglycan, increased TGFBR3 could compete
for UDP-glucuronate acid (GlcA) and UDP-xylose, both key elements for UGT1A9
activity, thereby potentially disrupting UGT associated resistance mechanisms and
increasing the efficacy of chemotherapy. We also narrowed down which pathways
differentiated patient outcomes for either INHA or TGFBR3. For positive outcomes, we
found that INHA was associated with PD-L1, Ras, and Rap1 signaling pathways. In adverse
outcomes, INHA was associated with Hippo, Wnt, and cell cycle pathways. Wnt has been
shown to regulate INHA transcription in rat adrenal cortex and could increase INHA
expression in certain tumors to promote tumorigenesis

37.

Recent evidence indicates

increased PD-L1 in dendritic cells in INHA-/- mice 318. We speculate that increased INHA
in tumors may inhibit PD-L1 expression perhaps via antagonistic effect on other TGF-β
members, increasing anti-tumor immune responses.
There are currently no other cancer prognostic models based on our three assessed
genes. The selected prognostic model showed high accuracy (96.7%) with 98.42%
sensitivity and 91.56% specificity (Table 3.3). Moreover, most prognostic cancer models
are directed to either a specific cancer type (e.g., breast, prostate) or a cancer stage (e.g.,
lymph node metastases, phases). Our model includes at least ten tumor types, is in the top
two for sensitivity, and among the second quartile of specificities on assessment of 48
prognostic cancer models 319-322. Thus, the INHA-TGFBR3-ENG signature has pan-cancer
prognostic value. Interestingly, there were very few SMAD and canonical TGF-β
associated pathway members that were part of the probit analysis (S5 Table). However,
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several genes associated with non-SMAD TGF-β signaling were included, such as
MAP2K6, FZD5, and PHLPP1 which are associated with MAPK, Wnt, and Akt signaling
pathways respectively

323.

Much of TGF-β’s functions in EMT, invasion and metastasis

have been associated with non-SMAD pathways

323,324

which are more likely to involve

the coreceptors TGFBR3 and ENG. Hence it was not surprising that such non-SMAD
pathways were predominant in the INHA-TGFBR3-ENG analysis.
Clustering analysis for genes correlated with INHA, TGFBR3, or ENG in cancers
(Figure 3.5) revealed ENG and TGFBR3 had very few genes correlated exclusively to one
or the other. As both receptors share similar structures and interact with common ligands
207,

this is not unexpected. Similarly, since ENG and TGFBR3 had significant common

gene associations this resulted in common pathways. For instance, a strong correlation with
ECM-receptors and Rap1 signaling was observed. ENG has been shown to bind leukocyte
integrins, promoting invasion

325,

and ECM remodeling during fibrosis

been shown to regulate integrin localization and adhesion to ECM

326.

327.

TGFBR3 has

ENG alone was

associated with natural killer cell-mediated cytotoxicity consistent with previous findings
showing anti-endoglin therapy augmented immune response in tumors by increasing NK
cells, CD4+, and CD8+ T lymphocytes 328.
In conclusion, our pan-cancer analysis of the inhibin-activin network reveals a
prognostic signature capable of accurately predicting patient outcome. Gene signatures
from our analysis reveal robust relationships between INHA, ENG, and TGFBR3 and other
established cancer biomarkers. Survival analysis implicated members of the inhibin-activin
network in cancers previously unstudied as well as corroborated previous findings. Further
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analysis of the role of the inhibin-activin network in cancer and relationship to other cancer
associated genes, as well as validation as predictive biomarkers to chemotherapy is needed.
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Table 3.1 p values and Hazard Ratios (HR) from survival curves assessing the impact of
INHA, INHBA, INHBB, TGFBR3, and ENG on patient survival. Survival curves were
generated in KM Plotter for all cancer types. Survival curves represent overall survival,
progression free survival (marked with *), or relapse free survival (marked with #).
Type

Subtype

Variable

INHA

INHBA

Breast
Cancer#

All

p value
Hazard
Ratio (HR)
p value
Hazard
Ratio (HR)
p value
Hazard
Ratio (HR)
p value
Hazard
Ratio (HR)
p value
Hazard
Ratio (HR)
p value
Hazard
Ratio (HR)
p value
Hazard
Ratio (HR)
p value
Hazard
Ratio (HR)
p value
Hazard
Ratio (HR)
p value
Hazard
Ratio (HR)
p value

5.9E-8
0.74

p53 Mutated

TNBC

Luminal A

Luminal B

HER2+

Serous
Ovarian
Cancer*

All

p53 Mutated

Lung
Cancer

All

Adenocarninom
a
Squamous Cell
Carcinoma
Gastric
Cancer

All

HER2-

HER2+

Cervical
Cancer

Squamous Cell
Carcinoma

TGFBR3

Eng

0.29
1.06

INHB
B
0.034
0.89

2.2E-12
0.69

.0014
0.84

0.0056
1.99

0.2
1.37

0.3
1.29

0.41
0.82

0.12
1.46

0.068
1.49

0.064
1.5

0.9
1.03

0.061
0.67

0.68
1.09

0.00021
0.72

0.95
1.01

0.0014
0.76

1.5E-6
0.66

0.23
0.9

5.9E-5
0.67

0.33
1.1

0.78
0.97

0.076
0.84

0.0057
0.76

0.25
0.8

0.65
0.92

0.54
1.13

0.14
0.75

0.2
0.78

1.5E-6
0.71

0.047
1.16

0.16
0.9

0.096
1.18

0.0032
0.82

0.00039
1.55

0.0055
1.42

0.079
1.23

0.039
0.79

0.0098
1.36

00.00029
1.26

0.37
0.94

0.78
1.02

3.4E-7
0.65

0.0056
1.2

5.6E-9
2.01

0.59
1.07

0.18
1.17

5.5E-10
0.46

1.6E-8
1.98

0.14

0.26

0.67

0.97

0.79

Hazard
Ratio (HR)
p value
Hazard
Ratio (HR)
p value

1.2

0.87

1.05

1.01

1.03

3.2E-8
1.66

0.0053
1.31

2E-15
2.17

0.019
1.23

2E-9
1.78

0.00055

0.21

0.0013

8E-7

Hazard
Ratio (HR)
p value
Hazard
Ratio (HR)
p value
Hazard
Ratio (HR)

1.53

1.17

5.3E13
2.64

1.48

1.75

0.0029
1.51

2.2E-5
1.78

7.6E-5
1.69

0.035
1.33

0.0032
1.62

0.022
1.97

1.5E-5
2.94

0.19
1.38

0.35
1.32

0.12
1.49
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Head and
Neck
Cancer
Kidney
Cancer

Squamous Cell
Carcinoma
Renal Clear
Cell Carcinoma
Renal Papillary
Cell Carcinoma

Liver
Cancer

Hepatocellular
Carcinoma

Endometri
al
Cancer
Brain
Cancer

Uterine Corpus

Glioblastoma

Low Grade
Glioma

p value
Hazard
Ratio (HR)
p value
Hazard
Ratio (HR)
p value
Hazard
Ratio (HR)
p value
Hazard
Ratio (HR)
p value
Hazard
Ratio (HR)
p value
Hazard
Ratio (HR)
p value

0.035
1.42

0.00044
1.68

0.0037
1.52

0.00049
0.62

0.0022
0.64

7.1E-06
1.98

0.19
0.82

0.32
1.16

2.1E-7
0.46

8.6E-6
0.51

0.0062
2.24

0.00011
3.16

0.0056
2.33

0.042
0.53

0.091
1.68

0.38
1.17

0.02
1.52

0.093
1.39

0.021
0.67

5.6E-6
0.45

0.046
0.65

0.11
0.71

0.011
0.49

0.01
1.74

0.025
0.54

0.019
1.27

0.94
1.08

0.2767
1.02

0.832
1.085

0.318
0.806

0.005

0.6925

0.046

0.7413

0.0004

Hazard
Ratio (HR)

0.7088

0.955

1.208

0.9907

1.675
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Table 3.2 p values and Hazard Ratios (HR) from survival curves assessing the
relationship between TGFBR3/ENG and INHA on patient survival. Survival curves
were generated in KM Plotter for all cancer types. Survival curves represent overall
survival, progression free survival (marked with *), or relapse free survival (marked with
#) for patients expressing high or low mRNA (split by median) of the indicated gene.
Type

Subtype

All
Breast

#

p53 Mutated

Ovarian*

p53 Mutated

All
Lung
Adenocarcinoma

Kidney

Type

Renal Clear Cell

Subtype

All
Breast#
p53 Mutated

Ovarian*

Lung

p53 Mutated

All
Adenocarcinoma

Variable

INHA

TGFBR3

INHA
and
TGFBR3

p value
Hazard
Ratio
(HR)
p value
Hazard
Ratio
(HR)
p value
Hazard
Ratio
(HR)
p value
Hazard
Ratio
(HR)
p value
Hazard
Ratio
(HR)
p value
Hazard
Ratio
(HR)

5.9E-8

4E-11

4.5E-12

INHA in
high
TGFBR3
Patients
0.00026

INHA in
Low
TGFBR3
Patients
5.9E-6

0.74

0.69

0.68

0.74

0.74

0.0056

0.41

0.82

0.27

0.015

1.99

0.82

0.95

1.5

2.29

0.00039

0.039

0.1

0.021

0.00075

1.55

0.79

0.83

1.51

1.74

0.00029

3.4E-7

1.4E-6

4.4E-5

0.18

1.26

0.65

0.73

1.49

1.12

5.6E-9

5.5E-10

3.1E-7

1.7E-5

1.6E-8

2.01

0.46

0.53

2.49

1.98

7.1E-06

2.1E-7

3.3E-05

0.2

9.0E-06

1.98

0.46

0.53

1.42

2.75
INHA in
Low
ENG
Patients
0.0027

Variable

INHA

ENG

INHA
and ENG

p value
Hazard
Ratio
(HR)
p value
Hazard
Ratio
(HR)
p value
Hazard
Ratio
(HR)
p value
Hazard
Ratio
(HR)
p value

5.9E-8

0.0014

7.4E-6

INHA in
High
ENG
Patients
0.0043

0.74

0.84

0.78

0.79

0.79

0.0056

0.12

0.057

0.26

0.035

1.99

1.46

1.6

0.69

2.24

0.00039

0.0098

0.00091

1.8E-6

0.18

1.55

1.36

1.49

2.12

0.8

0.00029

0.0056

0.063

0.47

5.8E-8

1.26

1.2

1.13

1.07

1.66

5.6E-9

1.6E-8

5.6E-12

0.14

0.00041
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Kidney

Renal Clear Cell

Hazard
Ratio
(HR)
p value
Hazard
Ratio
(HR)

2.01

1.98

2.3

1.25

2.12

7.1E-06

8.6E-6

4.5E-05

0.072

2.5E-06

1.98

0.51

0.53

1.53

2.6
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Table 3.3 Prognostic performance of each delineated probit model.
INHA model

Cancer types (+)

•
•
•
•

Endometrial;
BC lum A;
BC lum B;
Low grade glioma

Cancer types (-)

•
•
•
•
•
•
•
•

Head and Neck;
Stomach;
Cervical;
Renal Clear Cell;
BC p53 mut;
Lung adenocarcinoma;
Renal Papillary Cell;
Glioblastoma.

TGFBR3 model
•
•
•
•
•
•
•

Renal Clear Cell;
Lung adenocarcinoma;
Renal Papillary Cell;
Head and Neck;
BC lum A;
Liver;
OVCA p53 mut

•
•
•

Stomach;
Endometrial;
OVCA p53 WT.

Genes in model

43

37

Specificity

90.76%

98.42%

Sensitivity

93.17%

91.56%

False positives ratio

6.83%

8.44%

False negative ratio

9.24%

1.58%

Accuracy

92.25%

96.70%
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Figure 3.1. Expression and gene alterations of inhibin and activins. A) Genes encoding
INHA, INHBA, and INHBA produce monomeric α and β subunits. These subunits combine to
form either homo or heterodimers representing mature inhibin A, inhibin B, activin A, and
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activin B. B) TCGA base analysis of gene alteration frequencies of INHA, INHBA, INHBB,
TGBFR3, and ENG. C) Analysis of gene expression levels, also from TCGA sets, of the same
genes as in (B) in a subset of cancer types and subtypes. Analysis included 16 studies and 6258
samples. D) DepMap analysis of cell line dependency from indicated cancer types on each of
the genes in (B). E) Venn diagram illustrating the number of common dependent genes for
each gene in (B). All numeric data are available in S1 Table. Abbreviations – CNS: Central
Nervous System; LumA: Luminal A; LumB: Luminal B; mut: mutated; WT: wild-type.

111

Figure 3.2. Impact of INHA, INHBA, INHBB, TGFBR3, and ENG on patient survival in
indicated cancers. A-E) Forest Plot with Hazard Ratios (HR) of indicated genes generated
from KM Plotter or data from cBioportal. Black dots represent HR that are not statistically
significant (p > 0.05) and red dots represent HR that are statistically significant (p < 0.05). FH) Representative Kaplan Meier curves for INHA, TGFBR3, and ENG. Event-free survival in
indicated cancers using median to separate expression (lighter shade indicates bottom patients
expressing bottom 50% and darker shade top 50%). Survival curves represent OS for all
cancers except breast cancer (RFS) and ovarian cancer (PFS). Top plots show cancer types
where the gene is a negative predictor of survival, and bottom plots show cancer types where
the gene is a negative predictor.
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Figure 3.3. ROC plots and gene expression of indicated genes for different chemotherapy
regimens. A) ROC curves, in which performance ability was verified (i.e., AUC > 0.6), were
plotted for ENG, INHA, INHBA, and TGFBR3. B) Gene expression for each investigated gene
between responders and non-responders for the assessed pharmacological treatments. The
sample sizes for each group were the following: ANT LUMA, n = 474; TAX LUMA, n = 375;
TAX HER2, n = 143; TAX TNBC, n = 290; TAX OVCA, n = 851. Abbreviations: ANT:
anthracycline; TAX: taxane; LUMA: luminal A; TNBC: triple-negative breast cancer; OVCA:
serous ovarian cancer.
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Figure 3.4. Gene signatures and expression patterns for cancers where INHA, TGFBR3,
or ENG predicted survival outcomes. A) Cancer types in which either INHA TGFBR3 or
ENG had either positive (+) or negative (-) survival outcomes had their RNA-seq gene data
correlation clustered for either low or high degree of correlations to each INHA, TGFBR3 or
ENG as indicated. B) mRNA abundance of a subset of common genes obtained from pairwise
comparisons of the top correlated genes from the positive outcome with the genes that had
lower correlations in the negative outcome set, and vice-versa. mRNA expression was assessed
in each cancer set. * p < 0.05 ** p < 0.01 *** p < 0.001 **** p < 0.0001 (A) Pathway analysis
after BioGRID assessment of the significant genes from (B), ranked with a ratio of significance
between sets from the positive and negative outcomes for each gene.
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Figure 3.5. Functional analysis of gene signatures between INHA and TGFBR3 and INHA
and ENG. A) Supervised clustering of correlations of RNA-seq data between INHA, TGFBR3,
and ENG was performed to obtain sets of positive and negatively correlated genes for each set.
B) Common genes that were found in each group of correlated genes (e.g., negative correlation
to INHA vs. positive to TGFBR3 and all combinations) is presented. C) KEGG pathway
analysis for groups of genes correlated with the indicated combination. Unique pathways with
an FDR below 0.05 were identified for the comparisons and are presented.
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Appendix A Results and Discussion
This appendix includes supportive data for inhibin protein expression in HEY tumors and
patient ascites, and INHA expression regulated by hypoxia across a cell line panel.
Figure A.1.A. Schematic of the assembly of monomeric inhibin (left) and dimeric inhibin
protein (right) as detected in HEY tumors. The monomeric inhibin protein is produced as
a pro-peptide containing three domains: pro-domain (~9kDa), N (~23kDa), and C
(~20kDa). As described in the introduction (1.1), these domains can be cleaved to form the
mature C peptide however non-cleaved forms of inhibin are secreted and bioactive.
Unprocessed dimeric inhibin can also be secreted, as shown on the right, which contains
the noncleaved inhibin subunits linked by a di-sulfide bond to the noncleaved beta subunit
made up of a pro-domain (~32kDa) and a beta domain (~13kDa).
Figure A.2.B. To better understand what forms of inhibin protein were being produced by
tumors, inhibin from HEY tumors in Figure 2.11A was detected through western blotting
using the R1 anti-inhibin antibody. Using lysates from HEY PLK01 and shINHA tumors,
we confirmed that we did have an effective knockdown of INHA. HEY tumors produced
both unprocessed ProN/C (~55kDa) protein as well as partially processed ProC
(~27kDa). No fully processed inhibin was detected which was not surprising as it is
typically cleared from circulation in 3-6 minutes329.
Figure A.2.C. In Figure A.2.B, lysates were run on a reducing gel meaning dimeric forms
of inhibin protein were not detectable, as alpha and beta subunits are linked by a disulfide
bond. To determine if the inhibin protein detected in the tumors was dimeric or free
inhibin, I ran HEY PLK01 tumor lysates and recombinant inhibin A on both reducing
(left) and non-reducing gels (right). Under reducing conditions (i), recombinant inhibin A
161

ran as the mature C form (~15kDa) and the tumor lysates ran as ProN/C (~55kDa) and
ProC (~27kDa). However, under non-reducing conditions, recombinant inhibin A ran as
the mature heterodimer C/ (~33kDa). Tumor lysates appeared as ProN/C (~55kDa),
indicating this form is secreted as free inhibin, and as ProNC/ProA/BA/B, meaning
some dimeric inhibin is being produced as well. Since the inhibin subunit is common to
both inhibin A and inhibin B, I was unable to differentiate between the two but could be
determined with a specific beta subunit antibody. Taken together, this data shows that both
HEY tumors produce both unprocessed forms of free inhibin and dimeric inhibin protein.
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Figure A.1. Inhibin protein is detectable in HEY tumors. A) Schematic showing various
pre-processed and processed forms and sizes of monomeric inhibin and dimeric inhibin
protein. B) (i)Western blot analysis of HEY PLK01 and shINHA tumor lysates using antiinhibin R1 antibody. 40g of tumor lysate was run per lane and R1 antibody was used at
2g /mL dilution. (ii) Quantitation of western blot in (i) shown as each form of inhibin
detected normalized to GAPDH. MeanSEM, n=6. *, p<.05, unpaired t-test. C) Western
blot of lysates from HEY tumors and recombinant inhibin A ran under (i) reducing or (ii)
non-reducing conditions and immunoblotted with anti-inhibin R1 antibody. 40g of
tumor lysate run per lane or 5ng of recombinant inhibin A and R1 antibody was used at
2g /mL dilution.
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Figure A.2. In Chapter 2 (Figure 2.3B), total inhibin ELISA was performed on a cohort of
patient ascites fluid (AF) at Duke. Here, I performed the same ELISA on a separate, smaller
cohort of patient ascites samples obtained from Penn State. In Table A.1, the histology and
stage corresponding to each ascites sample is also shown. AF10, which was from a patient
with a granulosa cell tumor, had the highest inhibin levels that was followed by AF8 and
AF17 which were from high grade serous patients. These three samples had elevated levels
of inhibin compared to the cohort in Chapter 2 while the remaining samples in this cohort
had similar levels to those shown previously. Taken together, this data shows for the first
time that inhibin levels are elevated in the ascites fluid of ovarian cancer patients.
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Figure A.2. Inhibin expression in patient ascites fluid. Total inhibin ELISA of ascites
fluid from 7 ovarian cancer patients using the Ansh Total inhibin ELISA kit. (AF: ascites
fluid).
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Table A.1. Patient information for inhibin ELISA on ascites fluid. Histology and data
for corresponding ascites fluid samples shown in Figure A.2.
Sample ID
AF8
AF10

Histology
High Grade Serous
Granulosa Cell Tumor

Stage
IIIC
1A

AF14
AF15
AF17
AF18
AF19

Adenocarcinoma
Adenocarcinoma
High Grade Serous
High Grade Serous
Unknown

4
4
2C
4
Unknown
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Table A.2. As described in Chapter 2 (Figure 2.1), a panel of ovarian cancer cell lines was
tested to see INHA expression changes in response to hypoxia but only a select few were
included. Here, I have listed the entire panel of cell lines that I tested which include human
ovarian cell lines, mouse ovarian cell lines, a human prostate cell line, and a mouse triple
negative breast cell line. The table below details the name, species or origin, cancer subtype
and the extent and whether the cell line increased INHA in response to hypoxia or CoCl2.
Not all cell lines increase INHA in response to hypoxia indicating potential for another
mechanism of regulation. As mentioned in the Chapter 2 discussion, in adrenocortical
tumors, aberrant methylation has been reported within the proximal HRE site of the INHA
promoter79. It is possible that there are different methylation patterns within the promoters
of the cell lines tested which prevent transcriptional regulation of INHA by hypoxia. Future
studies are required to further delineate how INHA in regulated in cancer.
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Table A.2. INHA expression in cancer cell line panel in response to hypoxia. Cell lines
tested for INHA expression in response to hypoxia. INHA expression was measured by
qRT-PCR after exposure to hypoxia for 24hrs and normalized to normoxia.
Cell Line

Species

Type

Hypoxia
Responsive

Normalized
increase in INHA
expression
5.28-times
4.4-times

CoCl2
Responsive

PA1
OVCAR5

Human
Human

Teratocarcinoma
High Grade Serous

Yes
Yes

SKOV-3

Human

No

OV-90

Human

Serous
cystadenocarcinoma
High Grade Serious

Yes

Yes

3.9-times/not
significant
4.8-times

Not Tested

HEY

Human

High Grade Serous

Yes

4-times

Not tested

HEY T30

Human

Yes

3.5-times

Not tested

Human

High Grade Serous
(Taxol resistant)
High grade serous

HEYA8

No

Not tested

OVCAR3

Human

High grade serous

No

OVCAR433

Human

No

OVCA420

Human

ES-2

Human

Serous
adenocarcinoma
Serous
adenocarcinoma
Clear cell carcinoma

A2780

Human

Ovarian Endometroid

Yes

1.8-times/not
significant
1.7-times/not
significant
1.1-times/not
significant
0.67times/significant
1.01-times/not
significant
3.17-times

HEK293

Human

Yes

6.4-times

Not tested

PC3

Human

Human Embryonic
Kidney
Prostate

No

Not Tested

4T1

Mouse

No

ID8 Ashwini

Mouse

ID8 p53-/-

Mouse

No

ID8 EMD

Mouse

Triple Negative
Breast Cancer
Ovarian Surface
Epithelium
Ovarian Surface
Epithelium
Ovarian Surface
Epithelium

2-times/not
significant
4.9-times/not
significant
1.05-times/not
significant
1.25/not significant

Yes

4.1-times

Not Tested

ID8ip2Luc

Mouse

Yes

4-times

No

No
No

No

Ovarian Surface
Epithelium
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Yes
Yes

No
Not tested
Not tested
Not tested
Not tested

Not Tested
Not tested
Not tested
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